[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1304
1. Li L, Su LP, Ma L, Zhao J, Zhu L, Zhou YA: [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma].
  • OBJECTIVE: To explore the expression and clinical significance of P-glycoprotein (P-gp)/mdr1mRNA, multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) in newly diagnosed non-Hodgkin's lymphoma.
  • METHODS: mdr1 mRNA of in 41 patients with non-Hodgkin's lymphoma was assayed by semi-quantitative RT-PCR.
  • (1) Among the 41 cases, the positive expression of P-gp protein was detected in 8 cases, MRP in 7 cases, LRP in 15 cases, and mdr 1 mRNA in 11 cases. (2) The P-gp and LRP levels in NHL were significantly higher than those in control group, but MRP wasn't.
  • CONCLUSION: The data of this study indicate that P-gp and LRP expressions but not MRP expression are important in the mechanism of drug resistance associated with a poor clinical outcome in previously untreated NHL.
  • [MeSH-major] Drug Resistance, Multiple. Lymphoma, Non-Hodgkin / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Child. Drug Resistance, Neoplasm. Female. Humans. Lactate Dehydrogenases / blood. Lymph Nodes / metabolism. Male. Middle Aged. Neoplasm Staging. P-Glycoproteins. RNA, Messenger / metabolism. Remission Induction. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615260.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 1.1.- / Lactate Dehydrogenases
  •  go-up   go-down


2. Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, Chanock S: Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet; 2007 Apr;121(2):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma.
  • In a population-based case-control study of non-Hodgkin lymphoma (NHL) (n = 518 cases, 597 controls) among women in Connecticut, we analyzed one or more single nucleotide polymorphisms (SNPs) in ten candidate genes (AKR1A1, AKR1C1, AKR1C3, CYBA, GPX1, MPO, NOS2A, NOS3, OGG1, and SOD2) that mediate oxidative stress directly or indirectly in the NADPH oxidase-dependent respiratory burst.
  • Polymorphisms in AKR1A1 and CYBA were significantly associated with increased risk of NHL.
  • There was a 1.7-fold (95% CI = 1.2-2.4, P = 0.0047) increased risk of NHL for individuals who were variant homozygous for the AKR1A1 (IVS5 + 282T > C) SNP.
  • The effect was most pronounced for risk of diffuse large B-cell lymphoma, but risk estimates were non-significantly elevated for other common B-cell histologies and T-cell lymphomas as well.
  • In addition, individuals variant homozygous for the CYBA (Ex4 + 11C > T) SNP had a 1.6-fold (95% CI = 1.1-2.4, P = 0.019) increased risk of NHL that was particularly pronounced for T-cell lymphoma (OR = 3.5, 95% CI = 1.3-9.6, P = 0.013), but was also associated with non-significant increased risks for each of the common B-cell histologies.
  • These results suggest that SNPs in genes related to the oxidative stress pathway may be associated with increased risk of NHL.
  • [MeSH-major] Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Heterozygote. Homozygote. Humans. Middle Aged. Odds Ratio. Oxidative Stress. Risk


3. Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, Forman SJ, Bhatia S, Baker KS: Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant; 2007 Oct;13(10):1153-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.
  • We determined the prevalence of self-reported late-effects in survivors of autologous hematopoietic cell transplantation (HCT) for Hodgkin lymphoma (HL, n = 92) and non-Hodgkin lymphoma (NHL, n = 184) using a 255-item questionnaire and compared them to 319 sibling controls in the Bone Marrow Transplant Survivor Study.
  • HL and NHL survivors of autologous HCT have a high prevalence of long-term health-related complications and require continued monitoring for late effects of transplantation.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2101-8 [11956271.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):387-91 [11571512.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2015-23 [12393427.001]
  • [Cites] Br J Haematol. 2003 May;121(3):462-8 [12716369.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3431-9 [12885835.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] JAMA. 2004 May 19;291(19):2335-43 [15150205.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1898-906 [15172972.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4926-33 [15611507.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):599-608 [15659507.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4215-22 [15701723.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Clin Lymphoma Myeloma. 2005 Sep;6(2):122-30 [16231850.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2735-42 [16284986.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):138-51 [16443512.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):605-11 [16446333.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2912-9 [16339404.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6487-93 [17085663.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1878-86 [17119114.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(11):1191-6 [10849532.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):242-52 [11134219.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • (PMID = 17889351.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078938-03; United States / NCI NIH HHS / CA / CA078938-02; United States / NCI NIH HHS / CA / K23 CA085503; United States / NCI NIH HHS / CA / R01 CA078938-03; United States / NCI NIH HHS / CA / R01 CA078938-04; United States / NCI NIH HHS / CA / R01 CA078938-01A2; United States / NCI NIH HHS / CA / CA078938-04; None / None / / R01 CA078938-01A2; United States / NCI NIH HHS / CA / R01 CA078938; United States / NCI NIH HHS / CA / R01 CA078938-02; United States / NCI NIH HHS / CA / K23 CA85503-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS31872; NLM/ PMC2083636
  •  go-up   go-down


Advertisement
4. Chang DT, Amdur RJ, Pacholke H, Mendenhall NP, Morris CG, Byer GA, Olivier KR: Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques? Am J Clin Oncol; 2009 Apr;32(2):145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xerostomia in long-term survivors of aggressive non-Hodgkin's lymphoma of Waldeyer's ring: a potential role for parotid-sparing techniques?
  • BACKGROUND: The degree of xerostomia in patients treated for intermediate-and high-grade non-Hodgkin lymphoma (NHL) of Waldeyer's ring (WR) is unknown.
  • METHODS AND MATERIALS: Fifteen patients treated for stage I-IV NHL of WR with radiotherapy (RT) were administered a xerostomia questionnaire.
  • CONCLUSIONS: Xerostomia in survivors WR NHL is a detectable toxicity with severity like that in head and neck squamous cell carcinoma patients who receive ipsilateral parotid irradiation, and warrants parotid-sparing RT techniques.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Mantle-Cell / radiotherapy. Parotid Gland / radiation effects. Radiation Injuries / etiology. Xerostomia / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Intensity-Modulated. Surveys and Questionnaires. Survivors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307951.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Smedby KE, Hjalgrim H, Chang ET, Rostgaard K, Glimelius B, Adami HO, Melbye M: Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res; 2007 Nov 15;67(22):11074-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood social environment and risk of non-Hodgkin lymphoma in adults.
  • Better hygiene and sanitation and decreasing family size parallel the increasing incidence of non-Hodgkin lymphoma (NHL) in many populations around the world.
  • However, whether sibship size, birth order, and crowding are related to adult NHL risk is not clear.
  • We investigated how family structure and childhood social environment were related to the risk of NHL and NHL subtypes in a large Scandinavian population-based case control study with 6,242 participants aged 18 to 74 years.
  • Having four or more siblings was associated with a moderately increased risk of NHL, compared with having no siblings (OR 1.34, 95% CI 1.11-1.62, P(trend) < 0.001).
  • High household crowding was also positively associated with risk of NHL.
  • Results were slightly stronger for diffuse large B-cell and T-cell lymphomas than for other major NHL subtypes.
  • Our findings add to the evidence that large sibship size, late birth order, and childhood crowding are associated with an elevated risk of NHL.
  • [MeSH-major] Environment. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Denmark. Female. Humans. Male. Middle Aged. Odds Ratio. Risk. Risk Factors. Social Class. Sweden


6. Karipidis KK, Benke G, Sim MR, Fritschi L, Vajdic C, Kricker A, Armstrong B: Non-Hodgkin lymphoma and occupational radiation exposure assessed using local data. Occup Med (Lond); 2009 Sep;59(6):437-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma and occupational radiation exposure assessed using local data.
  • BACKGROUND: Our previous investigation of occupational exposure to ionizing radiation using a Finnish job-exposure matrix (JEM) showed no association with non-Hodgkin lymphoma (NHL) in a population-based case-control study in Australia.
  • AIMS: To determine whether occupational exposure to ionizing radiation assessed using an Australian JEM is associated with NHL.
  • METHODS: We analysed 694 NHL cases, first diagnosed between 1 January 2000 and 31 August 2001 and 694 controls from south-eastern Australia, matched by age, sex and region of residence.
  • CONCLUSIONS: The application of an Australian JEM did not provide evidence for an association between NHL and occupational exposure to ionizing radiation and is consistent with previous analyses.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Occupational Diseases / epidemiology. Occupational Exposure / statistics & numerical data. Radiation, Ionizing
  • [MeSH-minor] Adult. Aged. Australia / epidemiology. Female. Humans. Logistic Models. Male. Middle Aged. Risk Factors


7. Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N: The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psychooncology; 2009 May;18(5):554-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis.
  • INTRODUCTION: Although much is known about the efficacy, toxicity, and direct costs of treatment for follicular lymphoma (FL), there is no data assessing the impact of this diagnosis on the work productivity of affected individuals.
  • Patients with a diagnosis of FL or other indolent non-Hodgkin's lymphoma completed questionnaires assessing health status, work productivity, and activity impairment.
  • Prior to lymphoma diagnosis, over 71% of patients were working while 14% were retired.
  • CONCLUSIONS: Although few patients with indolent lymphoma identified significant impairment in productivity, many were unable to continue employment following diagnosis, needed to miss days from work, or imposed a significant burden on caregivers.
  • [MeSH-major] Burnout, Professional / epidemiology. Burnout, Professional / psychology. Efficiency, Organizational / statistics & numerical data. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / psychology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / psychology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Caregivers / psychology. Cross-Sectional Studies. Female. Health Status. Humans. Male. Middle Aged. Quality of Life / psychology. Surveys and Questionnaires. Unemployment / psychology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18942670.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • Ultrasonography and computed tomography scans may be helpful in the diagnosis of focal hepatic lymphoma.
  • Image-guided fine-needle biopsy with histopathology of the liver lesions is the gold standard for the diagnosis of hepatic lymphoma.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


9. Kim S, Kim HJ, Park JS, Lee J, Chi HS, Park CJ, Huh J, Suh C: Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol; 2005 Oct;84(11):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
  • We conducted a prospective randomized comparative observation of the mobilization with a single dose (10 microg kg once a day) or split dose (5 microg kg twice a day) of lenograstim following chemotherapy in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma (NHL) patients.
  • Chemotherapy was cyclophosphamide 4 g/m2 for MM and ESHAP with or without Rituximab for NHL.
  • We could not observe statistically significant differences between a single-dose and split-dose lenograstim following chemotherapy in enhancing the mobilization of PBPCs in MM or NHL patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization. Lymphoma, Non-Hodgkin / drug therapy. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hematopoietic Stem Cells / physiology. Humans. Male. Middle Aged. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132903.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down


10. Mai W, Meng H, Jin J, Wang L: Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol; 2006 Nov;77(5):445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
  • T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis.
  • We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy.
  • To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Boronic Acids / administration & dosage. Lymphoma, T-Cell / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Bortezomib. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Synergism. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930138.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Mangasarova IaK, Magomedova AU, Kravchenko SK, Zvonkov EE, Kremenetskaia AM, Vorob'ev VI, Mar'in DS, Gubkin AV, Skidan NI, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Vorob'ev AI: [Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment]. Ter Arkh; 2010;82(7):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment].
  • All the 15 patients received PCT according to the modified NHL-BFM-90 program: 4 to 6 courses depending on the response to the therapy; 10 (66.6%) and 5 (33.3%) patients had 4 and 6 courses, respectively; for consolidating purpose, 11 (78.5%) patients were prescribed radiotherapy applied to the mediastinum in a cumulative dose of 36 Gy due to the fact that they had a residual mass.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Mediastinum
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / immunology. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853612.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


12. Dean R, Masci P, Pohlman B, Andresen S, Serafino S, Sobecks R, Kuczkowski E, Curtis J, Maciejewski J, Rybicki L, Kalaycio M, Hsi E, Theil K, Bolwell BJ: Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant; 2005 Dec;36(12):1049-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
  • We prospectively determined pre-transplant and post transplant DC levels, including DC1 and DC2 subset levels, in 53 patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL) undergoing autologous HSCT.
  • These findings suggest a relationship between DC reconstitution and survival following autologous HSCT for DLBC NHL.
  • [MeSH-major] Dendritic Cells / cytology. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Cell Proliferation. Cell Transplantation. Female. Flow Cytometry. Granulocyte Colony-Stimulating Factor / metabolism. Hematopoietic Stem Cell Mobilization. Humans. Lymphoma. Male. Middle Aged. Models, Statistical. Prognosis. Prospective Studies. Recurrence. Stem Cell Transplantation. Stem Cells / cytology. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247431.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


13. Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L: Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis; 2008 Jan-Feb;40(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis were AML (n=16), ALL (n=7), NHL (n=3), MM (n=2) and CML (n=1).
  • [MeSH-minor] Adult. Cause of Death. Cell Separation / methods. Graft vs Host Disease. Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Histocompatibility. Humans. Melphalan / administration & dosage. Middle Aged. Muromonab-CD3 / administration & dosage. Survival Rate. Thiotepa / administration & dosage. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vidarabine / toxicity

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869547.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / Muromonab-CD3; 905Z5W3GKH / Thiotepa; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


14. Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F: Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. Med Oncol; 2010 Sep;27(3):942-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
  • In aggressive non-Hodgkin lymphoma (NHL), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisolone) regimen has been standard for decades, and rituximab has increased response rates and survival in CD20 positive patients, recently.
  • The aim of this prospective trial was to evaluate the long-term efficacy and toxicity of MINE as a consolidation treatment in aggressive NHL patients who had achieved CR or unproven CR after six cycles of CHOP in the first line setting.
  • Two patients had grade two neuropathy, one had grade three mucositis and another one had non-neutropenic pneumonia.
  • MINE regimen seems to be effective as a consolidation regimen, especially, in intermediate/high risk patients and has low early and late toxicities, and it warrants to be evaluated in phase III randomised trials with rituximab in CD20 positive aggressive NHL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Fever / chemically induced. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Kaplan-Meier Estimate. Male. Mesna / administration & dosage. Mesna / adverse effects. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Peripheral Nervous System Diseases / chemically induced. Prednisolone / administration & dosage. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1018-26 [2474057.001]
  • [Cites] Oncology. 1997 Sep-Oct;54(5):376-9 [9260598.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Acta Oncol. 1995;34(7):937-40 [7492384.001]
  • [Cites] Acta Oncol. 1996;35(2):165-70 [8639311.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):58-62 [2333524.001]
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):149-62 [18474000.001]
  • (PMID = 19787462.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MINE protocol; VAP-cyclo protocol
  •  go-up   go-down


15. Shetty S, Dawes P, Ruske D, Al-qudah M, Lyons B: Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study. N Z Med J; 2006;119(1240):U2129
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eight adult patients with significant sialorrhoea were referred from an inpatient rehabilitation unit, GP referral, and internal medicine department.
  • This is an easily performed procedure with low morbidity and can be recommended as a first-line intervention in the treatment of adult sialorrhoea.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Injections / methods. Male. Middle Aged. Submandibular Gland. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Botox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924280.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


16. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol; 2009 Oct 1;27(28):4767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
  • PURPOSE: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients.
  • Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible.
  • CONCLUSION: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hematopoietic Stem Cell Transplantation / methods. Heterocyclic Compounds / administration & dosage. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Diarrhea / etiology. Double-Blind Method. Female. Headache / etiology. Humans. Infusions, Subcutaneous. Kaplan-Meier Estimate. Male. Middle Aged. Nausea / etiology. Prospective Studies. Transplantation, Autologous. Treatment Outcome. Young Adult


17. Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, Szucs TD, Jackisch C, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU): Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer; 2008 Nov;16(11):1299-309
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goals of this study were to assess the incidence and risk of chemotherapy-induced neutropenia, febrile neutropenia (FN) and dose limitations in breast cancer and lymphoma patients undergoing chemotherapy in Europe.
  • PATIENTS AND METHODS: Four hundred forty-four breast cancer and 305 lymphoma patients undergoing chemotherapy at 66 practices in five European countries participated in this prospective, observational study.
  • Lymphoma patients experienced higher incidences of FN (non-Hodgkin lymphoma (NHL) 22%; Hodgkin lymphoma (HL) 15%) and grade 4 neutropenia (NHL 54%; HL 40%).
  • Multivariate regression models indicated that first cycle FN, age > or = 65 years and Eastern Co-operative Oncology Group > 1 were associated with low RDI in breast cancer and lymphoma, while colony-stimulating factor (CSF) primary prophylaxis appeared to be protective in lymphoma only.
  • Primary CSF prophylaxis was provided to 9% of breast cancer, 28% of NHL and 19% of HL patients.
  • CONCLUSIONS: Neutropenia and low RDI remain serious problems in both breast cancer and lymphoma populations undergoing chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Breast Neoplasms / drug therapy. Lymphoma / drug therapy. Neutropenia / chemically induced. Neutropenia / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Europe / epidemiology. Female. Humans. Incidence. Middle Aged. Models, Statistical. Multivariate Analysis. Prospective Studies. Regression Analysis. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2006 Dec;100(3):255-62 [16705366.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1205-12 [16766587.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Cancer. 2006 May 15;106(10):2258-66 [16575919.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4302-11 [15381684.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):901-6 [7877646.001]
  • [Cites] Support Care Cancer. 2006 Sep;14(9):901-9 [16622653.001]
  • [Cites] J Natl Compr Canc Netw. 2003 Jul;1(3):440-54 [19761076.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):963-77 [2348230.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4524-31 [14673039.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] N Engl J Med. 1991 Jul 18;325(3):164-70 [1711156.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):725-30 [14551505.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11 [9719081.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):277-83 [17952688.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1430-6 [1381626.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):427-37 [15967836.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2069-76 [14959849.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):886-98 [16257797.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2062-8 [14647139.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7437-44 [16234511.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):228-37 [14716755.001]
  • (PMID = 18351398.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Liu L, Zhang M, Zou P: Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. Oncology; 2008;74(1-2):96-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment.
  • OBJECTIVES: The study was devised to detect expression of polo-like kinase 1 (PLK1) in non-Hodgkin's lymphoma (NHL) and assess its value as a new target for NHL treatment.
  • METHODS: The expression of PLK1 in NHL was detected by immunohistochemical techniques.
  • Lymphoma cells were transfected with RNA interference plasmid targeted against PLK1 gene.
  • RESULTS: The expression rate of PLK1 in NHL was 63.6% (56/88).
  • In B cell NHL and T cell NHL, PLK1 expression had relationships with systemic symptom, lactate dehydrogenase level and International Prognostic Index scores.
  • PLK1 overexpression was associated with shortened event-free survival and was an independent prognostic factor for NHL.
  • PLK1 depletion by RNA interference plasmid in lymphoma cell lines could lead to cell growth suppression, cell cycle arrest and apoptosis induction.
  • CONCLUSIONS: PLK1 overexpression is an adverse predictive factor in NHL and PLK1 could be a new therapeutic target for NHL.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Lymphoma, Non-Hodgkin / genetics. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis. Cell Cycle. Cell Proliferation. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18547964.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


19. Bracci PM, Holly EA: Tobacco use and non-Hodgkin lymphoma: results from a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control; 2005 May;16(4):333-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco use and non-Hodgkin lymphoma: results from a population-based case-control study in the San Francisco Bay Area, California.
  • OBJECTIVE: Investigate the association between tobacco use and non-Hodgkin lymphoma (NHL).
  • METHODS: Tobacco-use data were collected during in-person interviews in a population-based case-control study of NHL (N=1593 patients, N=2515 controls) conducted in the San Francisco Bay Area between 1988 and 1995.
  • RESULTS: NHL was not associated with overall tobacco use, intensity or duration of cigarette smoking in women or men.
  • However, ORs were increased for NHL among men who used any non-cigarette tobacco alone (OR=1.7), non-cigarette tobacco and cigarettes (OR=1.4), multiple types of non-cigarette tobacco alone (OR=2.1) and smokeless tobacco alone (OR=4.0).
  • In analyses stratified by sex and age, ORs for NHL associated with cigarette smoking in general were above unity among those aged > or =60 years.
  • ORs for follicular lymphoma were increased in men who used cigarettes and other tobacco, cigars alone and smokeless tobacco alone.
  • Diffuse large-cell lymphoma in men was associated with use of cigarettes and other tobacco, and multiple types of non-cigarette tobacco.
  • CONCLUSION: Our data do not support an association between overall tobacco use and all NHL in women or men.
  • Further analyses are warranted in larger studies to evaluate non-cigarette tobacco use, tobacco-related biologic markers and genetic factors in the development of NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Smoking / epidemiology. Tobacco, Smokeless / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. California. Case-Control Studies. Comorbidity. Confidence Intervals. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Odds Ratio. Probability. Prognosis. Reference Values. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Rate. Urban Health

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Smokeless Tobacco.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953976.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 45614; United States / NCI NIH HHS / CA / CA 87014; United States / NCI NIH HHS / CA / CA 89745
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, Ko YH, Kim WS, Kim SJ: Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol; 2009 Nov;88(11):1099-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
  • Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce.
  • We report our results using the LMB protocol on Korean adult BL patients.
  • All of the non-CR patients died, including five PR and one with progressive disease.
  • In conclusion, the LMB protocol was effective for Korean adult BL patients.
  • However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Evaluation. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / epidemiology. Humans. Kaplan-Meier Estimate. Korea / epidemiology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sepsis / epidemiology. Sepsis / etiology. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288103.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Piselli P, Busnach G, Citterio F, Richiardi L, Cimaglia C, Angeletti C, Doringhet PV, Pozzetto U, Perrino ML, Serraino D: [Kidney transplant and cancer risk: an epidemiological study in Northern and Central Italy]. Epidemiol Prev; 2008 Jul-Oct;32(4-5):205-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) (27 cases observed, SIR = 82) and non-Hodgkins lymphoma (NHL) (18 cases observed a SIR = 6.4 were the most common cancers.
  • The transplant AF was 46.9%, largely due to KS (98.8%) and NHL (84.3%).
  • [MeSH-minor] Adult. Female. Humans. Italy / epidemiology. Male. Retrospective Studies. Risk Factors


22. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R: FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet; 2008 May;183(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
  • Combined with chemotherapy or alone, in maintenance/consolidation, it is used for the treatment of non-Hodgkin lymphoma (NHL).
  • The role of a polymorphism in a specific Fc gamma receptor gene, FcgammaRIIa, in the clinical outcome of patients with NHL was investigated in this study.
  • We characterized DNA samples from 64 non-Hodgkin lymphoma patients treated with rituximab using a polymerase chain reaction-restriction fragment length polymorphism method.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / genetics. Drug Resistance, Neoplasm / genetics. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide. Receptors, IgG / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Female. Gene Frequency. Humans. Male. Middle Aged. Pharmacogenetics. Prognosis. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474295.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Fc gamma receptor IIA; 0 / Receptors, IgG; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Cattaneo C, Facchetti F, Re A, Borlenghi E, Majorana A, Bardellini E, Casari S, Tucci A, Conti G, Rossi G: Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. Leuk Lymphoma; 2005 Jan;46(1):77-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral cavity lymphoma (OCL) seems to occur more frequently in HIV-positive patients, but it is presently unknown whether HIV-related immune deficit plays a role in modifying the prevalence and the characteristics of these lymphomas.
  • A comparison was made between cases of OCL occurring among 543 and 123 NHL consecutively diagnosed at a single center in immunocompetent and HIV-positive patients respectively.
  • Extranodal T/NK nasal-nasal-type lymphoma (ET/NK-NL) was observed in 3 of 9 immunocompetent patients, whereas plasmablastic lymphoma (PBL) was observed in 3 of 9 HIV-positive patients.
  • A higher frequency of oral cavity lymphoma was associated with HIV infection.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma / complications. Lymphoma / immunology. Mouth Neoplasms / complications. Mouth Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis


24. Vajdic CM, Fritschi L, Grulich AE, Kaldor JM, Benke G, Kricker A, Hughes AM, Turner JJ, Milliken S, Goumas C, Armstrong BK: Atopy, exposure to pesticides and risk of non-Hodgkin lymphoma. Int J Cancer; 2007 May 15;120(10):2271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy, exposure to pesticides and risk of non-Hodgkin lymphoma.
  • Pesticide exposure has been associated with non-Hodgkin lymphoma (NHL) risk in a number of studies, and two recent studies suggest that the increased risk may be confined to those with a history of asthma.
  • We examined the interaction between occupational pesticide exposure and atopy on risk of NHL in an Australian population-based case-control study.
  • The OR for NHL with substantial pesticide exposure and any history of asthma was 3.07 (95% CI 0.55-17.10) and with substantial pesticide exposure and no asthma history it was 4.23 (95% CI 1.76-10.16).
  • Although this study had limited power, the findings do not suggest modification of the association between pesticide exposure and NHL risk by asthma or atopic disease more generally.
  • [MeSH-major] Cocarcinogenesis. Hypersensitivity, Immediate / immunology. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / immunology. Occupational Exposure / adverse effects. Pesticides / poisoning
  • [MeSH-minor] Adult. Aged. Asthma / immunology. Case-Control Studies. Eczema / immunology. Food Hypersensitivity / immunology. Humans. Middle Aged. Rhinitis, Allergic, Seasonal / immunology. Risk Factors


25. Cil T, Altintas A, Isikdogan A, Batun S: Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma: a single center experience. Int J Hematol; 2009 Jul;90(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma: a single center experience.
  • In this present prospective study, we examined the prevalence of ANCA and related disease in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients in the southeast region of Turkey.
  • We examined 119 patients with previously or newly diagnosed NHL and 60 patients with HL for the presence of ANCA and related autoimmune diseases between December 2002 and February 2007.
  • There was statistically significant difference between patients with HL and NHL in terms of p-ANCA (p = 0.001) but none in c-ANCA (p = 0.111) positivity.
  • In addition, we did not detect any ANCA positivity in the NHL group.
  • [MeSH-major] Antibodies, Antineutrophil Cytoplasmic / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Turkey / epidemiology. Vasculitis / blood. Vasculitis / epidemiology. Vasculitis / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2001 Mar;60(3):293-5 [11171697.001]
  • [Cites] Blood. 1993 Apr 15;81(8):1996-2002 [8471761.001]
  • [Cites] Kidney Int. 1998 Mar;53(3):743-53 [9507222.001]
  • [Cites] J Autoimmun. 1993 Apr;6(2):197-205 [8499058.001]
  • [Cites] Semin Arthritis Rheum. 1995 Feb;24(4):231-41 [7740303.001]
  • [Cites] Semin Arthritis Rheum. 1995 Oct;25(2):134-42 [8578313.001]
  • [Cites] Rheumatology (Oxford). 2000 Apr;39(4):417-20 [10817775.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Curr Opin Rheumatol. 1992 Feb;4(1):39-46 [1543662.001]
  • [Cites] N Engl J Med. 2001 Aug 2;345(5):340-50 [11484692.001]
  • [Cites] Aust N Z J Med. 1994 Jun;24(3):282-7 [7980211.001]
  • [Cites] J Clin Rheumatol. 1997 Oct;3(5):279-81 [19078202.001]
  • [Cites] Curr Opin Rheumatol. 1997 Jan;9(1):75-9 [9110138.001]
  • [Cites] Br J Hosp Med. 1993 Nov 3-16;50(9):540-7 [8287253.001]
  • [Cites] Am J Med. 1992 Dec;93(6):675-82 [1466365.001]
  • [Cites] Rheumatol Int. 2002 Nov;22(6):233-7 [12426661.001]
  • [Cites] Clin Nephrol. 1992 Mar;37(3):124-30 [1348669.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Arthritis Rheum. 1999 Apr;42(4):751-6 [10211890.001]
  • [Cites] J Clin Lab Immunol. 1990 Aug;32(4):153-9 [1966931.001]
  • [Cites] Pathology. 1994 Apr;26(2):186-93 [8090592.001]
  • [Cites] Ulster Med J. 1996 May;65(1):55-7 [8686102.001]
  • [Cites] Lancet. 1995 Oct 7;346(8980):926-31 [7564726.001]
  • [Cites] Ann Intern Med. 1995 Dec 15;123(12):925-32 [7486487.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):43-8 [16501834.001]
  • [Cites] Ann Med Interne (Paris). 1991;142(7):486-504 [1789527.001]
  • [Cites] Infection. 1999 Mar-Apr;27(2):92-6 [10219637.001]
  • [Cites] Br J Haematol. 1986 May;63(1):143-7 [3707859.001]
  • [Cites] APMIS Suppl. 1989;6:12-3 [2660875.001]
  • [Cites] Minerva Med. 2008 Feb;99(1):7-14 [18299692.001]
  • [Cites] Eur J Med. 1992 Oct;1(6):337-42 [1341461.001]
  • [Cites] Leuk Lymphoma. 1993 Jan;9(1-2):49-54 [8477201.001]
  • [Cites] Am J Kidney Dis. 2000 Sep;36(3):E19 [10977812.001]
  • [Cites] Am J Med. 1995 Aug;99(2):207-16 [7625426.001]
  • [Cites] Immunobiology. 1990 Nov;181(4-5):406-13 [2099908.001]
  • (PMID = 19472034.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic
  •  go-up   go-down


26. Adelusola KA, Sabageh DO, Ukah CO: Lymphoreticular diseases in Nigerians. Afr Health Sci; 2008 Mar;8(1):20-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non Hodgkin's lymphoma (NHL) and tuberculosis were the most common lesions in lymph nodes and extranodal lymphoid tissues.
  • The most common pathological changes in bone marrow were NHL and reactive hyperplasia.
  • Patients with chronic lymphocytic leukaemia (CLL) had the highest mean age, which was significantly higher than in those with NHL (p=.001, 95% confidence interval -27.91 to -7.76).
  • CONCLUSION: NHL and tuberculosis should be high on the list of differential diagnosis of lymphadenopathy in Nigerians.
  • [MeSH-major] Burkitt Lymphoma. Lymphadenitis. Lymphoma, Non-Hodgkin. Tuberculosis, Lymph Node
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Bone Marrow / pathology. Child. Child, Preschool. Confidence Intervals. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Infant. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoid Tissue / pathology. Male. Middle Aged. Nigeria. Retrospective Studies. Spleen / pathology. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):327-30 [15101719.001]
  • [Cites] West Afr J Med. 2001 Apr-Jun;20(2):123-6 [11768010.001]
  • [Cites] Acta Trop. 1985 Mar;42(1):87-96 [2859755.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):29-33 [1573603.001]
  • [Cites] Mod Pathol. 1993 May;6(3):378-91 [8346187.001]
  • [Cites] Q J Med. 1993 Dec;86(12):811-7 [8108537.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2459-64 [15621760.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):471-5 [15621842.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S87-97 [15690645.001]
  • [Cites] Leuk Res. 2005 Dec;29(12):1371-80 [16183116.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] J Pathol. 1999 Dec;189(4):448-53 [10629542.001]
  • [Cites] Pediatr Surg Int. 2000;16(7):505-9 [11057553.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • (PMID = 19357728.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC2408537
  •  go-up   go-down


27. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, Prince HM: Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma; 2005 Nov;46(11):1575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years.
  • Patients with NHL were also matched by International Prognostic Index score.
  • Median age was 65 (range 60--76) with 22 MM and 18 NHL; 50% had 1 or more co-morbidity; 35% had cardiovascular co-morbidity vs. 18% of controls (p=0.075).
  • For NHL patients there were: 8 CR (44%) and 4 PR (22%), giving an ORR of 67%, vs. 83% for controls (p=0.3).
  • HDT is feasible and effective in selected patients 60 years with MM and NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / chemically induced. Drug-Related Side Effects and Adverse Reactions. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Transplantation, Autologous


28. Biswas G, Parikh PM, Nair R, Bhagwat R, Bakshi A, Prabhash K, Vora A, Gupta S, Pai VR, Menon H, Sastry PS: Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. J Assoc Physicians India; 2006 Jan;54:29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology was aggressive NHL in 35, indolent NHL in 22 and 7 cases were diagnosed as CLL.
  • Among NHL, sixteen were in early stage (I/II) and the remaining forty-one were in advanced stage (III/IV) of disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / drug effects. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Female. Humans. India. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Retrospective Studies. Rituximab. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649735.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, Folliot P, Chalastanis A, Muleris M, Hamelin R, Mercier D, Oliveira C, Seruca R, Chadburn A, Leblond V, Barete S, Gaïdano G, Martin A, Gaulard P, Fléjou JF, Raphael M, Duval A: The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. Int J Cancer; 2009 Nov 15;125(10):2360-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.
  • We investigated the biological, therapeutic and clinical features associated with MSI in immunodeficiency-related non-Hodgkin lymphomas (ID-RL).
  • Unlike other ID-RL, MSI ID-RL were primarily EBV-negative NHL of T-cell origin, and arose after long-term immunosuppression in patients who received azathioprine as part of their immunosuppressive regimen (p = 0.05) and/or who exhibited methylation-induced loss of expression of MGMT in tumor cells (p= 0.02).
  • [MeSH-major] Chromosomal Instability. DNA Mismatch Repair / genetics. Immunologic Deficiency Syndromes / genetics. Lymphoma, Non-Hodgkin / genetics. Microsatellite Instability
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adaptor Proteins, Signal Transducing / metabolism. Adenosine Triphosphatases / genetics. Adenosine Triphosphatases / metabolism. Adolescent. Adult. Aged. Case-Control Studies. Child, Preschool. Comparative Genomic Hybridization. DNA Methylation. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. MutS Homolog 2 Protein / genetics. MutS Homolog 2 Protein / metabolism. Mutation. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. O(6)-Methylguanine-DNA Methyltransferase / genetics. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / metabolism. Young Adult. ras Proteins / genetics. ras Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551857.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / KRAS protein, human; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


30. Zhong L, Huang WF: Better detection of Ig heavy chain and TCRγ gene rearrangement in plasma cell-free DNA from patients with non-Hodgkin Lymphoma. Neoplasma; 2010;57(6):507-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Better detection of Ig heavy chain and TCRγ gene rearrangement in plasma cell-free DNA from patients with non-Hodgkin Lymphoma.
  • This study aimed at comparing the properties of plasma cell-free DNA with the biopsy's DNA in order to evaluate the clinical significance of IgH and TCRγ gene rearrangement in plasma cell-free DNA from patients with non-Hodgkin's Lymphoma.
  • Plasma cell-free DNA were successfully extracted from 288 cases of newly diagnosed, refractory and relapsed NHL in total 360 patients (80%).But nothing was found in the other 72 remittent patients.
  • The positive percentage of IgH rearrangement in patients with B-NHL was 81% in plasma cell-free DNA and 77% in biopsy's DNA (P>0.05).
  • As to the ratio of TCRγ rearrangement in patients with T-NHL, the former was 44%, and the latter was 39% (P>0.05).
  • For NHL patients, detecting IgH and TCRγ gene rearrangement of plasma cell-free DNA has the same clinical significance as biopsy's DNA.
  • Moreover, it's more simple, convenient and non-invasive.
  • KEYWORDS: Lymphoma non-Hodgkin, plasma, cell-free DNA, gene rearrangement, immunoglobulin, heavy-chain gene, T-cell receptor.γ
  • [MeSH-major] DNA, Neoplasm / blood. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Female. Genes, Immunoglobulin. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845988.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


31. Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE: A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis; 2007 Dec;66(12):1627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.
  • OBJECTIVE: To investigate risk factors for non-Hodgkin's lymphoma (NHL) and analyse NHL subtypes and characteristics in patients with systemic lupus erythematosus (SLE).
  • A nested case control study on SLE patients who developed NHL during this observation period was performed with SLE patients without malignancy as controls.
  • Tissue specimens on which the lymphoma diagnosis was based were retrieved and reclassified according to the WHO classification.
  • NHLs of the subtype diffuse large B cell lymphoma (DLBCL) were subject to additional immunohistochemical staining using antibodies against bcl-6, CD10 and IRF-4 for further subclassification into germinal centre (GC) or non-GC subtypes.
  • RESULTS: 16 patients with SLE had NHL, and the DLBCL subtype dominated (10 cases).
  • The 5-year overall survival and mean age at NHL diagnosis were comparable with NHL in the general population-50% and 61 years, respectively.
  • Cyclophosphamide or azathioprine use did not elevate lymphoma risk, but the risk was elevated if haematological or sicca symptoms, or pulmonary involvement was present in the SLE disease.
  • CONCLUSIONS: NHL in this national SLE cohort was predominated by the aggressive DLBCL subtype.
  • The prognosis of NHL was comparable with that of the general lymphoma population.
  • [MeSH-major] Lupus Erythematosus, Systemic / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Aged. Antigens, Viral / analysis. Case-Control Studies. Confidence Intervals. Female. Herpesvirus 4, Human / immunology. Humans. Immunohistochemistry. In Situ Hybridization. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / virology. Male. Middle Aged. Risk Assessment. Survival Analysis. Sweden

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Semin Arthritis Rheum. 2007 Feb;36(4):246-55 [16996579.001]
  • [Cites] Rheumatology (Oxford). 2000 Oct;39(10):1147-52 [11035137.001]
  • [Cites] Lupus. 2001;10(6):394-400 [11434573.001]
  • [Cites] Lupus. 2001;10(7):500-4 [11480849.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1136-43 [11830458.001]
  • [Cites] Br J Dermatol. 2002 May;146(5):877-81 [12000388.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):554-8 [12006334.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Scand J Rheumatol. 2002;31(2):66-71 [12109649.001]
  • [Cites] Curr Rheumatol Rep. 2002 Aug;4(4):351-8 [12126588.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1543-50 [12794821.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):888-92 [102228.001]
  • [Cites] J Chronic Dis. 1978;31(11):691-6 [730824.001]
  • [Cites] Ann Rheum Dis. 1992 Apr;51(4):437-9 [1586239.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Lakartidningen. 1994 Feb 16;91(7):598, 603-5 [8114596.001]
  • [Cites] Arthritis Rheum. 1996 Jun;39(6):1050-4 [8651970.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):761-8 [9125261.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1725 [9324032.001]
  • [Cites] BMJ. 1998 Jul 18;317(7152):180-1 [9665898.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1481-90 [15880596.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1113-20 [15920553.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1507-9 [16162903.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] J Rheumatol. 2000 Mar;27(3):685-91 [10743809.001]
  • (PMID = 17517757.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral
  • [Other-IDs] NLM/ PMC2095297
  •  go-up   go-down


32. Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, Kobylka P, Cermak J, Brezinova J, Schwarz J, Markova J, Salaj P, Klamova H, Maaloufova J, Lemez P, Novakova L, Benesova K: CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis; 2008 May-Jun;40(3):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
  • CEBPA mutations were found in 14/152 (9.2%) of acute myeloid leukemia (AML) patients' samples, 6/143 (4.2%) of MDS patients' samples, 2/56 (3.6%) of non-Hodgkin's lymphoma (NHL) patients' samples and 2/39 (5.1%) of multiple myeloma (MM) patients' samples.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Lymphoma, Non-Hodgkin / genetics. Multiple Myeloma / genetics. Mutation. Myelodysplastic Syndromes / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data


33. Zepeda-Gomez S, Camacho J, Oviedo-Cardenas E, Lome-Maldonado C: Gastric infiltration of diffuse large B-cell lymphoma: endoscopic diagnosis and improvement of lesions after chemotherapy. World J Gastroenterol; 2008 Jul 21;14(27):4407-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric infiltration of diffuse large B-cell lymphoma: endoscopic diagnosis and improvement of lesions after chemotherapy.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of the non-Hodgkin's lymphoma (NHL) accounting for about 40% of all NHLs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endoscopy / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach / pathology. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Lymph Nodes / pathology. Medical Oncology / methods. Neoplasm Invasiveness. Neoplasm Metastasis


34. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B: Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol; 2009 Apr;63(5):793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity.
  • METHODS: Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin's lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen.
  • RESULTS: CALGB 9551 accrued 37 patients from April 1996 through October 2000; one patient with HD, 18 patients with indolent lymphoma, and 17 patients with aggressive lymphoma.
  • CONCLUSION: Single agent 9-AC has modest activity in aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Camptothecin / analogs & derivatives. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648813.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


35. Zhang C, Cui GH, Liu F, Wu QL, Chen Y: [The role of stromal cell derived factor-1/CXCR4 biological axis in tumor metastasis of non-Hodgkin lymphoma]. Zhonghua Yi Xue Za Zhi; 2007 Mar 13;87(10):695-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of stromal cell derived factor-1/CXCR4 biological axis in tumor metastasis of non-Hodgkin lymphoma].
  • OBJECTIVE: To study the expression of stromal cell derived factor-1 (SDF-1) and its receptor CXCR4 in non-Hodgkin lymphoma (NHL), and to investigate the role of this biological axis in tumor metastasis of NHL.
  • METHODS: Specimens of bone marrow were collected from 4 patients with NHL with bone marrow infiltration and 4 cases of NHL without bone marrow infiltration, and 4 patients with benign hepatopathy with normal myelogram.
  • Lymphoma specimens were collected from 7 cases of NHL and 3 cases of reactive proliferative lymphadenitis.
  • The CXCR4 expression on lymphoma cells freshly isolated from bone marrow and lymph node of the NHL patients were studied by flow cytometry.
  • The migration rate of the primary lymphoma cells towards rhSDF-1alpha was calculated.
  • RESULTS: The expression levels of CXCR4 on the lymphoma cells isolated from the bone marrow involved or not involved by NHL were both significantly higher than that of the mononuclear cells from normal bone marrow (both P < 0.01), whereas the CXCR4 expression level on the lymphoma cells from the lymph nodes of the NHL patients was also significantly higher than that of the mononuclear cells from the lymph nodes of reactive proliferative lymphadenitis (P < 0.01).
  • The SDF-1alpha mRNA expression level in the stromal cells isolated from the bone marrow involved by NHL was significantly higher than those of the stromal cells of bone marrow not involved by NHL and the normal bone marrow (both P < 0.01).
  • Moreover, the SDF-1alpha expression level in the lymph node stromal cells of all the NHL patients was also significantly higher than that of the patients with reactive proliferative lymphadenitis (P < 0.01).
  • Transwell assay revealed that all three kinds of primary lymphoma cells migrated towards rhSDF-1alpha effectively, and this migration was markedly inhibited by the addition of anti-CXCR4 monoclonal antibody to the lymphoma cells (all P < 0.01).
  • CONCLUSION: SDF-1/CXCR4 axis plays a uniquely important biological role in mediating tumor metastasis of NHL.
  • [MeSH-major] Chemokine CXCL12 / genetics. Lymphoma, Non-Hodgkin / pathology. Receptors, CXCR4 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553309.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


36. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, Schwaenen C, Wessendorf S, Spang R, Möller P, Hansmann ML, Bernd HW, Ott G, Hummel M, Stein H, Loeffler M, Trümper L, Zimmermann M, Reiter A, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe: Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood; 2008 Aug 15;112(4):1374-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials.
  • The spectrum of entities, the therapeutic strategy, and the outcome of mature aggressive B-cell non-Hodgkin lymphomas (maB-NHLs) differs between children and adolescents on the one hand and adult patients on the other.
  • Whereas adult maB-NHLs have been studied in detail, data on molecular profiling of pediatric maB-NHLs are hitherto lacking.
  • We analyzed 65 cases of maB-NHL from patients up to 18 years of age by gene expression profiling, matrix comparative genomic hybridization (CGH), fluorescent in situ hybridization (FISH), and immunohistochemistry.
  • We compared this group to a series of 182 previously published cases of adult maB-NHL.
  • Gene expression profiling reclassified 31% of morphologically defined diffuse large B-cell lymphomas as molecular Burkitt lymphoma (mBL).
  • The subgroups obtained by molecular reclassification did not show any difference in outcome in children treated with the NHL-Berlin-Frankfurt-Muenster (BFM) protocols.
  • No differences were detectable between pediatric and adult mBL with regard to gene expression or chromosomal imbalances.
  • This is the first report on molecular profiling of pediatric B-NHL showing mBL to be much more prominent in children than suggested by morphologic assessment.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Clinical Trials as Topic. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Male. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509088.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, Schmiegel W, Dührsen U, Halangk J, Iwan A, Sauerbruch T, Caselmann WH, Spengler U: Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Aug 1;12(15):4491-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma.
  • PURPOSE: Chronic hepatitis C carries the risk to develop mixed cryoglobulinemia (MC) and B-cell non-Hodgkin's lymphoma (B-NHL), possibly because viral antigens stimulate the host's inflammatory response via extracellular pattern recognition receptors (PRR).
  • To clarify this issue, we studied whether recognition of hepatitis C virus (HCV) proteins by PRR is involved in the pathogenesis of HCV-associated MC or B-NHL.
  • EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells of patients with HCV-associated B-NHL (n = 12), MC (n = 14), uncomplicated hepatitis C (n = 12), and healthy volunteers (n = 12) were incubated with the recombinant HCV proteins E2, core, and NS3 to study induction of cytokine production, stimulation of B-cell proliferation, and immunoglobulin secretion.
  • CONCLUSIONS: Increased secretion of IL-6 via stimulation of TLR2 by HCV core protein may play a role in the pathogenesis of hepatitis C-associated MC and B-NHL.
  • [MeSH-major] Cryoglobulinemia / etiology. Hepacivirus / immunology. Hepatitis C / complications. Interleukin-6 / biosynthesis. Lymphoma, B-Cell / etiology. Lymphoma, Non-Hodgkin / etiology. Viral Core Proteins / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Interleukin-8 / biosynthesis. Leukocytes, Mononuclear / immunology. Male. Middle Aged. Recombinant Proteins / blood. Recombinant Proteins / metabolism. Toll-Like Receptor 2 / genetics. Toll-Like Receptor 2 / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899594.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Interleukin-8; 0 / Recombinant Proteins; 0 / TLR2 protein, human; 0 / Toll-Like Receptor 2; 0 / Viral Core Proteins
  •  go-up   go-down


38. Linet MS, Taggart T, Severson RK, Cerhan JR, Cozen W, Hartge P, Colt J: Cellular telephones and non-Hodgkin lymphoma. Int J Cancer; 2006 Nov 15;119(10):2382-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular telephones and non-Hodgkin lymphoma.
  • Dramatic increase in hand-held cellular telephone use since the 1980s and excess risk of lymphoproliferative malignancies associated with radio-frequency radiation (RFR) exposures in epidemiological and experimental studies motivated assessment of cellular telephones within a comprehensive US case-control investigation of non-Hodgkin lymphoma (NHL).
  • A questionnaire ascertained cellular telephone use in 551 NHL cases and 462 frequency-matched population controls.
  • Among regular users compared to those who had never used hand-held cellular telephones, risks of NHL were not significantly associated with minutes per week, duration, cumulative lifetime or year of first use, although NHL was non-significantly higher in men who used cellular telephones for more than 8 years.
  • Little evidence linked use of cellular telephones with total, diffuse large B-cell lymphoma or follicular NHL.
  • [MeSH-major] Cell Phones. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Odds Ratio. Sex Distribution. Surveys and Questionnaires. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894556.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N02-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


39. Sipahimalani P, Spinelli JJ, MacArthur AC, Lai A, Leach SR, Janoo-Gilani RT, Palmquist DL, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR: A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. Int J Cancer; 2007 Nov 1;121(9):1967-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma.
  • Mutations in this gene cause the autosomal recessive syndrome ataxia telangiectasia (AT), an attribute of which is an increased risk of cancer, particularly lymphoma.
  • We have undertaken a population-based case/control study to assess the influence of genetic variation in ATM on the risk of non-Hodgkin lymphoma (NHL).
  • A number of the subtypes that constitute NHL have in common the occurrence of specific somatic translocations that contribute to lymphomagenesis.
  • We sequenced the promoter and all exons of ATM in the germline DNA of 86 NHL patients and identified 79 variants.
  • TagSNPs and the 6 putatively deleterious variants were genotyped in 798 NHL cases and 793 controls.
  • Our results indicate that common variants of ATM do not significantly contribute to the risk of NHL in the general population.
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Genotype. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Mutation / genetics


40. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP: Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant; 2005 Sep;36(5):437-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 10/17 patients achieved CR including 3/4 patients with chronic lymphatic leukaemia (CLL), 4/4 with mantle cell lymphoma (MCL), 3/4 with follicular NHL but 0/5 with aggressive NHL/Richters.
  • Low-grade NHL and MCL have a high response rate and sustained remissions following DLI.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Radiotherapy. Recurrence. Remission Induction. Retrospective Studies. Transplantation, Homologous


41. Wennberg RA, Tator CH: Concussion incidence and time lost from play in the NHL during the past ten years. Can J Neurol Sci; 2008 Nov;35(5):647-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concussion incidence and time lost from play in the NHL during the past ten years.
  • To evaluate the current state of this injury in the National Hockey League (NHL), we analyzed the concussion incidence and time lost from play due to concussions during the past ten NHL seasons.
  • METHODS: Data were obtained from a complete review of injury reports in two different sports media sources covering the NHL seasons 1997-98 through 2007-08.
  • CONCLUSIONS: Possibly related to injury reduction efforts, the number of concussions reported per season in the NHL has trended downward in recent years.
  • [MeSH-minor] Adult. Guidelines as Topic / standards. Humans. Incidence. Regression Analysis. Risk Factors. Safety Management / trends. Sick Leave / statistics & numerical data. Sick Leave / trends. Sports Equipment / adverse effects. Time Factors. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Concussion.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235451.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


42. Gupta S, Maheshwari A, Bhati GS, Desai S, Tongaonkar HB: Cervical lymphoma presenting as irregular vaginal bleeding. J Cancer Res Ther; 2006 Apr-Jun;2(2):72-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymphoma presenting as irregular vaginal bleeding.
  • Non-Hodgkin lymphoma (NHL) causes many deaths worldwide and its incidence is increasing.
  • We report an interesting case of NHL in a 35 year old female, who primarily presented with irregular bleeding per vaginum.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Uterine Cervical Neoplasms / complications. Uterine Hemorrhage / etiology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry


43. Ljubić N, Sucić M, Vasilj A, Lang N, Dominis M, Batinica AG, Jurković L, Siftar Z: Cytological detection of lymphoma in Douglas aspirate. Diagn Cytopathol; 2008 Oct;36(10):729-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological detection of lymphoma in Douglas aspirate.
  • Except in primary effusion lymphoma (PEL), serous effusions with lymphomatous cells in non-Hodgkin lymphoma (NHL) are not frequently seen as first manifestation of disease.
  • In NHL lymphoplasmacytic lymphoma (LPL) the spleen, lymph nodes, and bone marrow are frequently sites of disease and this type of NHL is usually associated with a serum paraprotein of IgM type accompanied by the clinical syndrome of Waldenström macroglobulinemia.
  • Our patient with NHL LPL type presented in this report had less frequently seen involvement of gastrointestinal tract and clinically was first manifested as effusion in Douglas space.
  • [MeSH-minor] Adult. Biopsy, Needle. Cell Differentiation. Cell Proliferation. Female. Humans

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773438.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Stasi R, Evangelista ML, Brunetti M, Bussa S, Maritati R, Turrini L, Taccogna S, Crescenzi A, Angelini F: Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports. Med Oncol; 2009;26(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports.
  • Primary breast lymphoma (PBL) is a rare form of extranodal non-Hodgkin's lymphoma (NHL), whose own specific biological characteristics still need to be fully defined.
  • We report two cases of primary diffuse large B-cell breast lymphoma, review the literature about this topic, and discuss treatment options.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antigens, CD45. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Breast / chemistry. Breast / pathology. Breast / physiopathology. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Injections, Spinal. L-Lactate Dehydrogenase / blood. Leucovorin / therapeutic use. Mastectomy, Segmental. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Neoplasm Staging. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Mar;18(3):398-405 [15492762.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Curr Med Chem. 2008;15(4):360-7 [18288990.001]
  • [Cites] Acta Oncol. 2000;39(2):135-9 [10859001.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Radiology. 1994 Jul;192(1):157-60 [8208929.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):571-6 [10048430.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Ann Diagn Pathol. 2006 Jun;10(3):144-8 [16730308.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3991-4008 [17577017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80 [17372233.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2602-11 [2249200.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • (PMID = 18461288.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.1.3.48 / Antigens, CD45; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


45. Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y, All Collaborators of the IDEC-C2B8 Study Group in Japan: Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Sci; 2010 Dec;101(12):2579-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
  • Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is one of the most frequently applied initial treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL); however, information on its long-term outcome is limited.
  • Sixty-five patients (94%) had follicular lymphoma, and 37 (55%) were at low risk, 23 (34%) at intermediate risk and seven (10%) at high risk according to the Follicular Lymphoma International Prognostic Index.
  • In conclusion, R-CHOP is a highly effective initial treatment for untreated indolent B-NHL in terms of ORR and OS; however, its long-term PFS is not good enough either in concurrent or sequential combination, warranting further investigations on post-remission therapy.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20942866.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Investigator] Aikawa K; Nakata M; Kasai M; Kiyama Y; Kano Y; Akutsu M; Miwa A; Takesako N; Itoh K; Igarashi T; Ishizawa K; Tobinai K; Kobayashi Y; Watanabe T; Ohyashiki K; Tauchi T; Hotta T; Ando K; Ohnishi K; Morishima Y; Ogura M; Kagami Y; Kinoshita T; Murate T; Nagai H; Tsushita K; Ohashi H; Kageyama S; Yamaguchi M; Taniwaki M; Ohno H; Ishikawa T; Suzuki T; Hiraoka A; Karasuno T; Murayama T; Mizuno I; Sakai A; Uike N; Maeda T; Tsukasaki K
  •  go-up   go-down


46. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, de Lima M, Cairo MS, Fürst S, Rio B, Dalley C, Carreras E, Harousseau JL, Mohty M, Taveira D, Dreger P, Sureda A, Gluckman E, Rocha V: Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol; 2009 Jan 10;27(2):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
  • PATIENTS AND METHODS: We evaluated 104 adult patients (median age, 41 years) who underwent unrelated donor UCBT for lymphoid malignancies.
  • Diagnoses were non-Hodgkin's lymphoma (NHL, n = 61), Hodgkin's lymphoma (HL, n = 29), and chronic lymphocytic leukemia (CLL, n = 14), with 87% having advanced disease and 60% having experienced failure with a prior autologous transplant.
  • CI of non-relapse-related mortality (NRM) was 28% at 1 year, with a lower risk in patients treated with low-dose total-body irradiation (TBI; P = .03).
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Neutrophils / cytology. Risk Factors. Transplantation Conditioning. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Apr 10;27(11):1923
  • (PMID = 19064984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Kenward K: Discipline of nurses: a review of disciplinary data 1996-2006. JONAS Healthc Law Ethics Regul; 2008 Jul-Sep;10(3):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Databases, Factual. Deception. Documentation / trends. Female. Fraud / trends. Humans. Male. Substance-Related Disorders / epidemiology. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776752.001).
  • [ISSN] 1539-073X
  • [Journal-full-title] JONA'S healthcare law, ethics and regulation
  • [ISO-abbreviation] JONAS Healthc Law Ethics Regul
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


48. Lee WJ, Purdue MP, Stewart P, Schenk M, De Roos AJ, Cerhan JR, Severson RK, Cozen W, Hartge P, Blair A: Asthma history, occupational exposure to pesticides and the risk of non-Hodgkin's lymphoma. Int J Cancer; 2006 Jun 15;118(12):3174-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asthma history, occupational exposure to pesticides and the risk of non-Hodgkin's lymphoma.
  • We previously reported that, although asthma did not increase the risk of non-Hodgkin's lymphoma (NHL), the risk from pesticide exposures was higher among asthmatics than that among nonasthmatics.
  • To further evaluate this finding, we analyzed data from a population-based case-control study of NHL conducted in Iowa, Detroit, Los Angeles and Seattle.
  • Cases (n = 668) diagnosed with NHL from 1998 to 2000 and controls (n = 543) randomly selected from the same geographical areas as that of the cases were included in this analysis.
  • Odds ratios (OR) for the risk of NHL from potential occupational exposure to pesticides tended to be higher among asthmatics (OR = 1.7; 95% CI 0.3-9.1) when compared with that among nonasthmatics (OR = 0.9; 95% CI 0.6-1.5).
  • The risks of NHL associated with pesticide exposure were also higher among asthmatics who had history of hospitalization (OR = 2.1; 95% CI 0.2-29.0) or daily medication for asthma (OR = infinite) than those among asthmatics who did not have such histories.
  • Our results support the previous finding that the risk of NHL from pesticide exposure may be greater among asthmatics.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [Cites] Lancet. 1992 Feb 29;339(8792):539-41 [1346889.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):451-5 [3383143.001]
  • [Cites] Am J Epidemiol. 1992 Aug 1;136(3):287-95 [1415150.001]
  • [Cites] Allergy. 1997 Feb;52(2):144-54 [9105518.001]
  • [Cites] Pediatrics. 1997 May;99(5):695-703 [9113946.001]
  • [Cites] Toxicol Ind Health. 1999 Jan-Mar;15(1-2):119-32 [10188195.001]
  • [Cites] Toxicol Lett. 1999 Sep 5;108(2-3):285-95 [10511273.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):934-7 [15824166.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5485s-5488s [1394159.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):298-302 [15197786.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Toxicology. 2002 Apr 2;172(3):181-90 [11893417.001]
  • [Cites] Allergy. 2005 Sep;60(9):1098-111 [16076292.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1043-9 [12148884.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):327-34 [12846363.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • (PMID = 16395708.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / Z01 CP010120-10; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Pesticides
  • [Other-IDs] NLM/ NIHMS11202; NLM/ PMC1578637
  •  go-up   go-down


49. Seliem RM, Freeman JK, Steingart RH, Hasserjian RP: Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen and is used to treat B-cell non-Hodgkin lymphoma (B-NHL).
  • Few studies have been published examining the use of antibody panels to evaluate B-NHL treated with rituximab.
  • The authors performed a retrospective analysis of immunophenotypic changes and clinical outcome in 18 patients with B-NHL following rituximab therapy.
  • Nine of the 18 patients (50%) achieved complete or partial clinical remission and did not have morphologic evidence of lymphoma in the post-therapy samples.
  • These results show that in many cases of B-NHL persisting after rituximab therapy, CD20 expression decreases or is lost, raising the possibility of deletion or expression modulation of the CD20 gene in neoplastic cells.
  • This study also underscores the importance of using a panel of antibodies to evaluate rituximab-treated B-NHL.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540725.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


50. Niscola P, Cartoni C, Romani C, Brunetti GA, D'Elia GM, Cupelli L, Tendas A, de Fabritiis P, Mandelli F, Foà R: Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann Hematol; 2007 Sep;86(9):671-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, 85% of visceral pain syndromes were observed in patients affected by non-Hodgkin's lymphoma (NHL).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analgesics / therapeutic use. Child. Child, Preschool. Data Collection. Female. Home Care Services. Humans. Italy / epidemiology. Male. Middle Aged. Pain Management. Pain Measurement. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450359.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


51. Altieri A, Bermejo JL, Hemminki K: Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood; 2005 Jul 15;106(2):668-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database.
  • Non-Hodgkin lymphoma (NHL) consists of a heterogeneous group of tumors.
  • We used the Swedish Family-Cancer Database to calculate standardized incidence ratios (SIRs) for histopathology-specific subtypes of NHL in 4455 offspring with NHL whose parents or siblings were affected with different types of lymphoproliferative malignancies.
  • A familial history of NHL significantly increased the risk for NHL (SIRparent = 1.8; SIRsibling = 1.9) and for diffuse large B-cell lymphoma (SIRparent = 2.3), follicular lymphoma (SIRsibling = 2.3), and B-cell lymphoma not otherwise specified (NOS) (SIRsibling = 3.4).
  • For a parental history of histopathology-specific concordant cancer, the risks were significantly increased for diffuse large B-cell lymphoma (SIR = 11.8), follicular NHL (SIR = 6.1), plasma cell myeloma (SIR = 2.5), and chronic lymphocytic leukemia (SIR = 5.9).
  • Familial clusters for NHL seemed stronger in females and in siblings.
  • Our study provides the first quantification of the familial risks for NHL by histopathology.
  • The present findings give evidence for a strong familial association of NHL, with little differences in the magnitude of risks for various histopathologic subtypes.
  • The patterns of risks in parents and siblings support the hypothesis of an autosomal-dominant component for diffuse large B-cell NHL and a recessive one for follicular NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoproliferative Disorders / genetics
  • [MeSH-minor] Adult. Aged. Databases, Factual. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Male. Middle Aged. Multiple Myeloma / classification. Multiple Myeloma / epidemiology. Multiple Myeloma / genetics. Multiple Myeloma / pathology. Risk Factors. Sweden / epidemiology


52. Hagtvedt T, Aaløkken TM, Smith HJ, Graff BA, Holte H, Kolbenstvedt A: Enhancement characteristics of lymphomatous lymph nodes of the neck. Acta Radiol; 2010 Jun;51(5):555-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To prospectively compare CT contrast medium enhancement curves of a homogeneous population of 28 patients with lymphomatous lymph nodes of the neck with 20 controls; to compare enhancement curves before and after successful treatment and to compare nodes with Hodgkin lymphoma (HL) and nodes with non-Hodgkin lymphoma (NHL).
  • Seventeen of the patients in complete remission after lymphoma treatment were also examined.
  • Patients with HL and patients with NHL had similar enhancement curves except that those with NHL had higher values at 7 min.
  • No significant difference in mean percentage loss of enhancement was found between normal nodes and lymph nodes with HL before treatment, but there was a slightly significant difference between normal nodes and lymph nodes with NHL.
  • Before treatment the mean enhancement values of HL were significantly higher than those of NHL at 7 min.
  • [MeSH-major] Lymph Nodes / radiography. Lymphoma / radiography. Neck / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Contrast Media / administration & dosage. Female. Humans. Iohexol / administration & dosage. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429760.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


53. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia; 2007 Nov;21(11):2316-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary study end point was non-relapse mortality (NRM).
  • Histologies were non-Hodgkin's lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL), n=14) and Hodgkin's disease (HD, n=32).
  • The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001).
  • Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04).
  • RIC allogeneic SCT is a feasible and effective salvage strategy in both indolent and aggressive NHL.
  • [MeSH-major] Lymphoma / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Stem Cells / cytology. Stem Cells / metabolism. Time Factors. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597807.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. Yu XQ, Chen WH, O'Connell DL: Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer; 2010 May 24;10:231
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.
  • BACKGROUND: We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population.
  • METHODS: NHL cases diagnosed in 1985-2004 in New South Wales (NSW) were followed-up to the end of 2004.
  • Using a Poisson regression model adjusted for age group, sex, NHL subtype and time period (1990-1994, 1995-1999 and 2000-2004), we estimated excess risk of death after a diagnosis of NHL.
  • RESULTS: Compared with 1990-1994, after adjusting for age, sex and NHL subtype the relative excess risk of death was significantly lower (p < 0.0001) in 1995-1999 (0.89) and 2000-2004 (0.74).
  • CONCLUSION: It is likely that some benefit of adding rituximab to the standard chemotherapy for NHL has been experienced at the population level.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2344-50 [17107908.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):566-77 [12226004.001]
  • [Cites] Drugs. 2003;63(8):803-43 [12662126.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Stat Med. 2004 Jan 15;23(1):51-64 [14695639.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):138-43 [14744745.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):611-8 [15280640.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):2004-10 [8909323.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270-86 [15417650.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):73-81 [16170828.001]
  • [Cites] Am J Clin Oncol. 2007 Apr;30(2):163-71 [17414466.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Annu Rev Med. 2008;59:237-50 [18186705.001]
  • [Cites] Arch Intern Med. 2008 Mar 10;168(5):469-76 [18332290.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S107-9 [18813239.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):630-8 [16614102.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):228-9 [16682983.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):894-900 [16550595.001]
  • [Cites] J Intern Med. 2006 Aug;260(2):103-17 [16882274.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2417-22 [16964611.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2786-93 [16930993.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • (PMID = 20497580.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / 550002
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2886045
  •  go-up   go-down


55. Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group: Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol; 2006 Apr;85(4):257-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
  • For comparison, a historical cohort of patients was used and analyzed for "Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas (NHLs) based on Revised American Lymphoma (REAL) classification" in 1999.
  • Among the 1,098 NHL patients, the data of 214 DLBCL patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / standards. Cyclophosphamide / therapeutic use. Data Interpretation, Statistical. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / standards. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Korea. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / standards. Prednisone / therapeutic use. Regression Analysis. Retrospective Studies. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / standards. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416337.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ: Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer; 2006 Oct 1;107(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
  • Fifty-four adult patients with recurrent or refractory, low-grade non-Hodgkin lymphoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) were treated according to the RC/RCC regimens.
  • RESULTS: Thirty-three patients with B-CLL, 12 patients with LG-NHL and 9 patients with mantle cell lymphoma (MCL) entered the study.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Cladribine / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16948126.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


57. Yunus SA, Usmani SZ, Ahmad S, Shahid Z: Renal involvement in non-Hodgkin's lymphoma: the Shaukat Khanum experience. Asian Pac J Cancer Prev; 2007 Apr-Jun;8(2):249-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal involvement in non-Hodgkin's lymphoma: the Shaukat Khanum experience.
  • BACKGROUND: Primary lymphoma of genitourinary system is rare as these organs do not contain lymphoid tissue, however secondary involvement often occurs.
  • METHODS: Medical records of 901 patients with documented NHL seen at Shaukat Khanum Memorial Cancer Hospital & Research Center during 1995-2003 were studied for the incidence, histopathological, clinical and radiological correlation of renal involvement in NHL.
  • Histology was diffuse large cell lymphoma in 12(63%) patients.
  • [MeSH-major] Kidney Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Blood Urea Nitrogen. Female. Functional Laterality. Humans. Incidence. Male. World Health Organization

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696740.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


58. Niu Y, Shi Y, Zhou S, Pan F, Wu S, Liu P, Yang J, Han X, He X: Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. Int J Hematol; 2009 Jan;89(1):106-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma.
  • The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin's lymphoma (NHL).
  • Eighty-nine aggressive NHL patients who underwent high-dose therapy in combination with autologous stem cell transplantation (HDT/ASCT) between 1993 and 2006 were retrospectively studied.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Radiotherapy. Radiotherapy Dosage. Retrospective Studies. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):321-6 [10967573.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):22-30 [11136838.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1504-9 [15367411.001]
  • [Cites] Blood. 1996 May 1;87(9):3633-9 [8611687.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2399-404 [11001890.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Jun;41(6):363-6 [12137594.001]
  • [Cites] Blood. 2003 Sep 15;102(6):1989-96 [12676776.001]
  • [Cites] Oncologist. 1999;4(5):386-97 [10551555.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):48-55 [9440722.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):406-13 [11208832.001]
  • [Cites] Blood. 1976 May;47(5):747-56 [769864.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Nov;25(6):592-5 [14690571.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):332-9 [10637247.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2208-14 [15753460.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):897-906 [12610191.001]
  • [Cites] Blood. 1998 May 1;91(9):3148-55 [9558369.001]
  • (PMID = 19067117.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


60. Arora NK, Hamilton AS, Potosky AL, Rowland JH, Aziz NM, Bellizzi KM, Klabunde CN, McLaughlin W, Stevens J: Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivors. J Cancer Surviv; 2007 Mar;1(1):49-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivors.
  • Drawing upon experiences from a study of survivors of non-Hodgkin's Lymphoma (NHL), we discuss conceptual and methodological challenges to and opportunities for conducting population-based survivorship research using cancer registries.
  • MATERIALS AND METHODS: Survivors of aggressive NHL diagnosed between June 1998 and August 2001, 2-5 years prior to the study, were sampled from the Los Angeles Surveillance Epidemiology and End Results (SEER) registry.
  • CONCLUSIONS: The cancer registry served as a valuable resource for recruiting one of the largest population-based samples of NHL survivors.
  • [MeSH-major] Health Status. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / psychology. Registries / statistics & numerical data. Research Design. Survivors / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Female. Health Surveys. Humans. Los Angeles. Male. Middle Aged. Quality of Life. Surveys and Questionnaires. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Feb;16(2):501-14 [9469334.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] J Pers Soc Psychol. 1987 Aug;53(2):273-9 [3625467.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Sep;43(3):219-26 [12270778.001]
  • [Cites] J Health Commun. 2004 Sep-Oct;9(5):443-60; discussion 81-4 [15513791.001]
  • [Cites] J Clin Oncol. 2006 Nov 10;24(32):5149-53 [17093278.001]
  • [Cites] Health Educ Res. 1995 Mar;10(1):51-64 [10150421.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):116-23 [16000127.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Br J Cancer. 1997;75(6):914-20 [9062416.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2471-6 [15621762.001]
  • [Cites] J Health Soc Behav. 1995 Mar;36(1):1-10 [7738325.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):364-9 [15862722.001]
  • [Cites] Med Oncol. 2001;18(1):85-94 [11778974.001]
  • [Cites] Med Sci Sports Exerc. 2004 Feb;36(2):253-60 [14767248.001]
  • [Cites] Soc Sci Med. 1991;32(6):705-14 [2035047.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Med Care. 1991 Aug;29(8):786-98 [1875745.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2136-41 [14522370.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):39-49 [11773281.001]
  • [Cites] Qual Life Res. 1998 May;7(4):301-10 [9610214.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2565-76 [16258929.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1719-24 [10528021.001]
  • [Cites] Support Care Cancer. 2006 Aug;14(8):837-48 [16482448.001]
  • [Cites] Support Cancer Ther. 2004 Jan 1;1(2):119-26 [18628188.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1514 [17077350.001]
  • [Cites] Health Care Women Int. 2006 Jan;27(1):45-58 [16338739.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):248-66 [12903014.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1372-82 [7658498.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] JAMA. 1995 Jan 4;273(1):59-65 [7996652.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] JAMA. 2000 Jan 19;283(3):354-60 [10647798.001]
  • [Cites] Res Nurs Health. 1998 Feb;21(1):73-82 [9472239.001]
  • [Cites] J Pers Soc Psychol. 1994 Dec;67(6):1063-78 [7815302.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):81-90 [8901370.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] Health Psychol. 2000 Mar;19(2):155-64 [10762099.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1034-8 [2257209.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5814-30 [16043830.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4 Suppl 1):26-34 [15934515.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1719-26 [11742045.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Health Serv Res. 2003 Dec;38(6 Pt 1):1509-27 [14727785.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67 [15367568.001]
  • [Cites] Soc Sci Med. 2006 Jun;62(12):3133-45 [16413644.001]
  • [Cites] Med Care. 1998 Feb;36(2):126-37 [9475468.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1305-14 [11571747.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):321-8 [9839345.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3295-301 [10986063.001]
  • (PMID = 18648945.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR921930-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


61. Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M: Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci; 2006 Jan;27(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-nine patients with hematological malignancies (MM, ALL or NHL) treated with a conventional CPA dose (1g/m(2)) were recruited to this study.
  • Data was analyzed individually and by population pharmacokinetic methods, using non-linear mixed effect modeling.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bilirubin / blood. Cytochrome P-450 CYP2B6. Female. Genotype. Humans. Liver / enzymology. Male. Middle Aged. Mutation. Pharmacogenetics

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183265.001).
  • [ISSN] 0928-0987
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 1XBF4E50HS / 4-hydroxycyclophosphamide; 8N3DW7272P / Cyclophosphamide; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


62. Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai SK, Sanger M, Shet T, Subramanian PG, Muckaden M, Laskar S: A clinicopathologic study of mantle cell lymphoma in a single center study in India. Indian J Pathol Microbiol; 2008 Jul-Sep;51(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic study of mantle cell lymphoma in a single center study in India.
  • We present clinical features, histopathology and results of treatment in cases of mantle cell lymphoma (MCL) at our hospital.
  • We had 93 cases (2.1%) of MCL out of total 4301 cases of non-Hodgkin's lymphoma (NHL) in a 4-year period.
  • It included 68 cases (1.7%) of MCL from 3987 cases of NHL diagnosed on histopathology.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology. Lymphoma, Mantle-Cell / physiopathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / biosynthesis. Antigens, CD43 / biosynthesis. Antigens, CD5 / biosynthesis. Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Cyclin D1 / biosynthesis. Female. Gastrointestinal Tract / pathology. Hospitals. Humans. India. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723950.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD5; 0 / Antineoplastic Agents; 0 / CCND1 protein, human; 0 / UN1 sialoglycoprotein, human; 136601-57-5 / Cyclin D1
  •  go-up   go-down


63. Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M: High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol; 2005 Nov-Dec;23(6):877-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The evidence of an increased frequency of B-non Hodgkin's lymphomas (NHL) in patients with HCV and systemic autoimmune diseases suggests a close relationship between infection, autoimmunity and cancer.
  • Choosing the best therapy for patients affected either by HCV-related lymphoma or autoimmune disorders is not easy; in fact, some treatments may be accompanied by an excessive hepatic toxicity and may be followed by a reactivation of hepatitis.
  • RESULTS: In this paper we evaluate the role of anti-CD20 monoclonal antibody in mono-therapy in 10 patients with either indolent HCV-related lymphoma or autoimmune disease.
  • A very high rate of response, of both NHL and of the associated autoimmune disease, was observed (100% of clinical response), with no significant hepatic and extra-hepatic toxicity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Autoimmune Diseases / drug therapy. Hepatitis C, Chronic / complications. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396708.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


64. Yoong Y, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Litzow MR, Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Tefferi A, Elliott M, Snow DS, Hogan WJ, Markovic SN: The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma; 2005 Sep;46(9):1287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.
  • We hypothesized there is a continuous and not discrete relationship between ALC recovery and clinical outcome post-ASCT in NHL.
  • Therefore, we analyzed 274 consecutive patients who underwent ASCT for NHL between 1987 and 2001.
  • These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL.
  • [MeSH-major] Lymphocyte Count. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Kinetics. Male. Middle Aged. Prognosis. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109605.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90628-04A; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


65. Park SK, Kang D, Beane-Freeman L, Blair A, Hoppin JA, Sandler DP, Lynch CF, Knott C, Gwak J, Alavanja M: Cancer incidence among paraquat exposed applicators in the agricultural health study: prospective cohort study. Int J Occup Environ Health; 2009 Jul-Sep;15(3):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the total subjects, the risk for non-Hodgkin's lymphoma (NHL) in the exposed group was marginally elevated (Relative risk [RR], 1.47; 95% confidence interval [CI], 0.97-2.23) compared to the non-exposed group.
  • However, among the 24,667 applicators who supplied total life-time exposure days, the highest tertile of lifetime exposure-days (LE) and intensity-weighted lifetime exposure-days (IWLE) was not significantly associated with NHL risk (RR, 1.57; 95%CI, 0.57-4.23 for LE; RR, 1.42; 95%CI, 0.40-4.71 for IWLE, respectively) and there was no significant exposure-response trend (p-trend > 0.1).
  • There was some suggestion of a possible link between paraquat exposure and NHL risk in humans, but the inconsistency in exposure level trend suggests that this could be a chance finding.
  • [MeSH-major] Agricultural Workers' Diseases / epidemiology. Herbicides / toxicity. Lymphoma, Non-Hodgkin / epidemiology. Paraquat / toxicity
  • [MeSH-minor] Adult. Female. Humans. Incidence. Iowa / epidemiology. Male. Middle Aged. North Carolina / epidemiology. Prospective Studies. Risk

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Paraquat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dermatol. 1995 Jul;34(7):466-9 [7591408.001]
  • [Cites] Int J Radiat Biol. 1991 Dec;60(6):899-906 [1682402.001]
  • [Cites] Br J Ind Med. 1987 Mar;44(3):196-200 [3493801.001]
  • [Cites] Hum Toxicol. 1987 Jan;6(1):41-7 [3546085.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Dec 28;91(4):1302-8 [526305.001]
  • [Cites] Cell Tissue Res. 2004 Oct;318(1):225-41 [15258850.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):69-78 [15177642.001]
  • [Cites] Pest Manag Sci. 2004 Apr;60(4):340-9 [15119596.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Mar 1;165(5):683-9 [11874814.001]
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Mutat Res. 1993 Oct;319(2):89-101 [7692291.001]
  • [Cites] Int J Occup Environ Health. 2001 Oct-Dec;7(4):275-86 [11783857.001]
  • [Cites] Mutat Res. 1995 Apr;328(1):113-8 [7898500.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):365-74 [10405835.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Mutat Res. 1993 Aug;300(3-4):223-9 [7687022.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):809-12 [9635867.001]
  • [Cites] Teratog Carcinog Mutagen. 1997-1998;17(6):339-47 [9485542.001]
  • [Cites] Int J Epidemiol. 1996 Dec;25(6):1125-31 [9027515.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • (PMID = 19650582.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010119-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Herbicides; PLG39H7695 / Paraquat
  • [Other-IDs] NLM/ NIHMS232258; NLM/ PMC3058830
  •  go-up   go-down


66. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL: Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant; 2008 Sep;14(9 Suppl):8-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
  • For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients.
  • In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs).
  • The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years.
  • Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients.
  • Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML.
  • [MeSH-minor] Adult. Aged. Hematologic Neoplasms / therapy. History, 20th Century. History, 21st Century. Humans. Middle Aged. Registries. Survival Rate. Tissue Donors. Transplantation, Homologous. United States

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721775.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


67. Anderson LA, Gridley G, Engels EA, Morton LM, Cerhan JR, Cozen W, Severson RK, Davis S, Hartge P, Linet MS: Antibiotic use and risk of non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer; 2008 Jan 15;98(1):161-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibiotic use and risk of non-Hodgkin's lymphoma: a population-based case-control study.
  • Antibiotic use in 759 non-Hodgkin's lymphoma (NHL) patients and 589 controls was compared.
  • Neither total antibiotic use (odds ratio=0.7, 95% confidence interval=0.5-1.2), nor antibiotic use by site, was associated with total NHL, or NHL subtypes.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2003 Mar 15;157(6):510-6 [12631540.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):99-105 [12925963.001]
  • [Cites] J Clin Epidemiol. 2000 Mar 1;53(3):273-7 [10760637.001]
  • [Cites] Mutat Res. 2001 May;488(2):151-69 [11344042.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] Chem Biol Interact. 2002 Nov 10;142(1-2):155-73 [12399161.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Pharm Weekbl Sci. 1991 Apr 26;13(2):91-6 [1870949.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):840-9 [1643616.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Am J Epidemiol. 1995 Nov 15;142(10):1103-12 [7485055.001]
  • [Cites] Epidemiology. 1996 Mar;7(2):131-9 [8834551.001]
  • [Cites] Infection. 1996 Jul-Aug;24(4):275-91 [8875279.001]
  • [Cites] Drug Chem Toxicol. 1997 Aug;20(3):239-53 [9292279.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):934-7 [15824166.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):965-74 [16192343.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S3-12 [12734687.001]
  • (PMID = 18059393.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N02-PC-71105; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / Intramural NIH HHS / / ; None / None / / N01 PC065064
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2359683
  •  go-up   go-down


68. Na II, Kang HJ, Park YH, Lee SS, Yoo HJ, Choe DH, Ryoo BY, Yang SH: Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol; 2007 Jul;79(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia.
  • This study evaluated the applicability of prognostic factors commonly used for diagnosis of classical lymphoma outcomes to extranodal NK/T cell lymphoma, nasal type (NTCL).
  • Current study suggests that prognostic factors for NHL may be useful to predict the outcome of NTCL but the model should take LDH level and the prognostic weight of each factor into account.
  • [MeSH-major] Killer Cells, Natural / immunology. Lymphoma, T-Cell / classification. Nose Neoplasms / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598834.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


69. Pulte D, Gondos A, Brenner H: Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med; 2008 Mar 10;168(5):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) is the most common hematologic malignant neoplasm in adults.
  • We use the novel technique of period analysis to disclose the most recent trends in survival among adults diagnosed as having NHL on the population level with minimum delay.
  • METHODS: We estimated trends in 5- and 10-year relative survival in patients 15 years or older diagnosed as having NHL in the United States between 1990 and 2004 using data from the Surveillance, Epidemiology, and End Results (SEER) program.
  • CONCLUSIONS: Our period analysis discloses a strongly improved outlook for patients diagnosed as having NHL in recent years.
  • Changes in treatment of the disease and a decrease in the number of human immunodeficiency virus-related NHL cases attributable to highly active antiretroviral therapy are probably primarily responsible for these improvements.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Outcome Assessment (Health Care)
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Continental Population Groups / statistics & numerical data. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Risk Factors. SEER Program. Survival Analysis. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332290.001).
  • [ISSN] 0003-9926
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


70. Yang CJ, Chen MY, Hsieh SM, Sheng WH, Sun HY, Hung CC, Chang SC: Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan. J Microbiol Immunol Infect; 2010 Aug;43(4):278-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan.
  • BACKGROUND/PURPOSE: Non-Hodgkin's lymphoma (NHL) is the second most common acquired immunodeficiency syndrome-defining malignancy with a high mortality rate.
  • This study aimed to describe changes in the incidence and clinical characteristics of NHL in human immunodeficiency virus (HIV)-infected patients in a referral hospital for HIV care.
  • METHODS: The medical records of HIV-infected patients diagnosed with NHL between June 1994 and December 2006 were retrospectively reviewed.
  • RESULTS: During the 12-year period, 38 HIV-infected patients were diagnosed with NHL.
  • Before the introduction of highly active antiretroviral therapy (HAART) in April 1997, 9/175 HIV-infected patients (5.1%) developed NHL compared with 29/1,386 patients (2.1%) in the HAART era (p < 0.05).
  • CONCLUSION: The incidence of NHL in HIV-infected patients declined significantly in the HAART era.
  • Despite the introduction of HAART, the short-term survival of the patients with NHL remained poor.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Taiwan Society of Microbiology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20688287.001).
  • [ISSN] 1995-9133
  • [Journal-full-title] Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
  • [ISO-abbreviation] J Microbiol Immunol Infect
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


71. Roh JL, Huh J, Suh C: Primary non-Hodgkin's lymphomas of the major salivary glands. J Surg Oncol; 2008 Jan 1;97(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphomas of the major salivary glands.
  • METHODS: We retrospectively assessed 20 patients with previously untreated non-Hodgkin's lymphomas (NHLs) and histologically confirmed as having parenchymal involvement of the salivary glands.
  • RESULTS: At diagnosis, the 12 patients with MALT lymphoma had a greater mean age and longer duration than did the 8 patients with other NHLs (P < 0.05).
  • Eight of the 12 MALT lymphoma patients had recurrent episodes of salivary gland swelling and 5 had myoepithelial sialadenitis, Sjögren syndrome, or gastric MALT lymphoma; these were not observed in the 8 other NHL patients.
  • Compared with the latter group, the MALT lymphoma group had significantly greater five-year relapse-free (37.5% vs. 91.7%, P < 0.05) and disease-free (35.0% vs. 90.9%, P < 0.05) survival rates.
  • However, two MALT lymphoma patients with high-grade transformation had recurrences beyond the head and neck region.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17929252.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Koutros S, Holford TR, Hahn T, Lantos PM, McCarthy PL Jr, Risch HA, Swede H: Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. Leuk Lymphoma; 2007 Feb;48(2):357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA.
  • Moderately increased incidence rates have been observed during the spring for leukemias and Hodgkin's disease but few studies have been conducted of non-Hodgkin's lymphoma (NHL).
  • Our study consisted of 77,173 NHL patients in the Surveillance, Epidemiology, and End Results database diagnosed during 1973 - 99.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Seasons
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Male. Middle Aged. Registries. Risk Factors. SEER Program. Time Factors. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Feb;48(2):223-4 [17325879.001]
  • (PMID = 17325897.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67005; United States / NCI NIH HHS / CA / R25 CA47883
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


73. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM: High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol; 2010 Aug 10;28(23):3709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
  • PURPOSE: Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: A multicenter trial evaluated two or three weekly infusions of yttrium-90 ((90)Y) epratuzumab tetraxetan (humanized anti-CD22 antibody) in 64 patients with relapsed/refractory NHL, including 17 patients who underwent prior autologous stem-cell transplantation (ASCT).
  • Patients without prior ASCT obtained high OR rates of 71% (CR/CRu, 55%) across all NHL subtypes and (90)Y doses, even in poor-risk categories (refractory to last anti-CD20-containing regimen, 73% [CR/CRu, 60%]; bulky disease: 71% [CR/CRu, 43%]).
  • For patients with follicular lymphoma (FL), OR rates and median PFS increased with total (90)Y-dose, reaching 100% (CR/CRu, 92%) and 24.6 months, respectively, at the highest dose levels (> 30 mCi/m(2) total (90)Y-dose [1,110 MBq/m(2)]).
  • CONCLUSION: Fractionated anti-CD22 radioimmunotherapy provides high total doses of (90)Y, yielding high rates of durable CR/CRus in relapsed/refractory NHL, resulting in 20 mCi/m(2) x 2 weeks as the recommended dose for future studies.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / epratuzumab
  •  go-up   go-down


74. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer; 2005 Nov;45(6):753-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
  • Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma.
  • With systematic improvements in therapy over recent decades, the vast majority of children with NHL of all subtypes are now cured.
  • The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology


75. Fatnassi R, Bellara I: [Primary non-Hodgkin's lymphomas of the breast. Report of two cases]. J Gynecol Obstet Biol Reprod (Paris); 2005 Nov;34(7 Pt 1):721-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphomas of the breast. Report of two cases].
  • [Transliterated title] Les lymphomes malins non-hodgkiniens primitifs du sein: á propos de deux cas.
  • Non-hodgkin's lymphoma (NHL) represents 0.04 to 0.53% of all breast cancers.
  • We report two cases of primary non-hodgkin's lymphoma of the breast in two patients aged respectively 37 and 57 years.
  • The diagnosis of non-hodgkin's lymphoma was confirmed on histological examination of tumor biopsies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Mammography. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270012.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Hosny G, Farahat N, Hainaut P: TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett; 2009 Mar 18;275(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
  • Mutations of P53 have been reported as common mutations in solid tumours, including non-Hodgkin lymphoma, NHL, and have been implicated in drug resistance, aggression and poor prognosis.
  • Chronic infection with hepatitis C, HCV, has been associated in some studies with increased risk of NHL.
  • OBJECTIVE: Since previous studies have shown p53 mutations in the DNAs extracted from the NH lymphoid tumours, we have assessed the presence of p53 mutations from exons 5 to 9 in CFDNA in patients with NHL, from Alexandria, Egypt, where HCV is highly prevalent, in a first attempt case-control preliminary study.
  • METHODS: CFDNA was extracted from sera of 20 cases with NHL and 20 negative control individuals.
  • RESULTS: Concentrations of CFDNA were significantly higher among NHL patients compared to the negative control individuals indicating a very high release or turn-over of DNA from the tumour into the blood stream among NHL patients.
  • Mutations of p53 determined in NHL cases (30%) were of Arg-176 (1/20: 5%), Phe-238 (1/20: 5%), Ser-249 (2/20; 10%), Lys-249 (1/20: 5%) and Phe-250 (1/20: 5%).
  • However, Arg-213 polymorphism was found in 2 cases of NHL (10%) and in 1 case of controls (5%).
  • CONCLUSION: Our findings of higher DNA concentrations with some p53 mutations in CFDNA from patients with NHL that match the previous reported p53 mutations from tumour DNA may hold promises that CFDNA may serve as a convenient source of tumour-derived DNA to serve as a promising tool of a non-invasive, low-cost new strategy for earlier detection, diagnosis and follow up of the disease.
  • A large-scale prospective study utilizing CFDNA and DNA from tumours of NHL patients will be required to validate this first trial of utilizing CFDNA from NHL patients.
  • [MeSH-major] DNA / blood. Lymphoma, Non-Hodgkin / genetics. Mutation. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Case-Control Studies. DNA Primers. Egypt. Exons. Female. Hepatitis C, Chronic / complications. Humans. Male. Middle Aged. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046801.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


77. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood; 2005 Sep 1;106(5):1538-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
  • The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy results in significant improvement in clinical outcome for individuals with non-HIV-associated aggressive B-cell lymphoma.
  • To assess the potential risks and benefits of the addition of rituximab to CHOP for HIV-associated non-Hodgkin lymphoma (HIV-NHL) 150 patients receiving CHOP for HIV-NHL were randomized (2:1) to receive 375 mg/m(2) rituximab with each chemotherapy cycle (n = 99) or no immunotherapy (n = 50) in a multicenter phase 3 trial.
  • The addition of rituximab to CHOP in patients with HIV-NHL may be associated with improved tumor responses.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):821-41 [12852657.001]
  • [Cites] Annu Rev Med. 2004;55:477-503 [14746532.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1023-7 [9037360.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2675-80 [15503313.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2001 Jan 1;97(1):270-6 [11133771.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):155-63 [11148572.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):469-75 [11170956.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [CommentIn] Blood. 2006 Apr 1;107(7):3013-4 [16554491.001]
  • [CommentIn] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • (PMID = 15914552.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U01C-A070 072; United States / NCI NIH HHS / CA / U01CA070 054; United States / NCI NIH HHS / CA / U01CA070 062; United States / NCI NIH HHS / CA / U01CA70 058; United States / NCI NIH HHS / CA / U01CA070 080; United States / NCI NIH HHS / CA / U01CA070 019; United States / NCI NIH HHS / CA / U01CA083 038; United States / NCI NIH HHS / CA / U01CA083 035; United States / NCI NIH HHS / CA / U01CA083 118; United States / NCI NIH HHS / CA / U01CA071 375; United States / NCI NIH HHS / CA / U01CA070 079; United States / NCI NIH HHS / CA / U01CA070 047; United States / NCI NIH HHS / CA / U01CA070 081
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC1895225
  •  go-up   go-down


78. Magomedova AU, Vorob'ev AI: [International prognostic index in diffuse B large cell lymphosarcoma]. Ter Arkh; 2008;80(3):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy was also given to patients with stage I-II, 38 patients received NHL-BFM-90 PCT.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity / trends. Prognosis. Remission Induction / methods. Retrospective Studies. Survival Rate / trends

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18441690.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


79. Omoti CE, Halim NK: Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival. Niger J Clin Pract; 2007 Mar;10(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival.
  • We aim to determine the incidence and survival of the lymphoma patients in the Niger Delta region of Nigeria.
  • STUDY DESIGN: A study of 205 cases of lymphoma patients from 1993 to 2003.
  • Non-Hodgkin's Lymphoma (NHL) was the most frequent (83%) while Hodgkin's Lymphoma (HL) had an incidence of 17%.
  • The 1 year survival for patients with NHL and HL was 35.3% and 42.9% respectively.
  • We found a strong association between haemoglobin (Hb) and white blood cell count (WBC) at presentation and lyear survival in NHL patients (P=0.0003; P=0.0001) and HL patients (P=0.0001; P=0.0104) respectively.
  • Also, the mean Erythrocyte sedimentation rate (ESR) for lymphoma patients alive at lyear was significantly lower than those that died within 1 year (P=0.0001).
  • CONCLUSION: We conclude that NHL was the most common of the lymphoma seen in young adulthood in the Niger Delta region of Nigeria.
  • [MeSH-major] Hodgkin Disease / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hospitals, University. Humans. Incidence. Male. Middle Aged. Nigeria / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668708.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


80. Quinney HA, Dewart R, Game A, Snydmiller G, Warburton D, Bell G: A 26 year physiological description of a National Hockey League team. Appl Physiol Nutr Metab; 2008 Aug;33(4):753-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary purpose of this investigation was to examine the physiological profile of a National Hockey League (NHL) team over a period of 26 years.
  • The data were analyzed across years, between positions (defensemen, forwards, and goaltenders), and between what were deemed successful and non-successful years using a combination of points acquired during the season and play-off success.
  • In conclusion, this study revealed that the fitness profile for a professional NHL ice-hockey team exhibited increases in player size and anaerobic and aerobic fitness parameters over a 26 year period that differed by position.
  • However, this evolution of physiological profile did not necessarily translate into team success in this particular NHL franchise.
  • [MeSH-minor] Adolescent. Adult. Anthropometry / methods. Body Height / physiology. Body Mass Index. Canada. Energy Metabolism / physiology. Humans. Male. Skinfold Thickness. Time. Young Adult

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641719.001).
  • [ISSN] 1715-5312
  • [Journal-full-title] Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme
  • [ISO-abbreviation] Appl Physiol Nutr Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


81. Engels EA, Cho ER, Jee SH: Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol; 2010 Sep;11(9):827-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.
  • Whether chronic HBV infection increases risk of non-Hodgkin lymphoma (NHL) is unclear.
  • We aimed to assess the association between chronic HBV infection and subsequent development of NHL in a South Korean cohort.
  • We assessed incidence of NHL overall and of NHL subtypes, malignant immunoproliferation, Hodgkin's lymphoma, multiple myeloma, and various leukaemias.
  • Subsequently, 133 HBsAg-positive and 905 HBsAg-negative individuals developed NHL.
  • HBsAg-positive participants had an increased risk of NHL overall compared with those who were HBsAg-negative (incidence 19.4 vs 12.3 per 100,000 person-years; hazard ratio [HR] 1.74, 95% CI 1.45-2.09, adjusted for sex, age at baseline, and enrolment year).
  • Among NHL subtypes, HBsAg positivity was associated with increased risk of diffuse large B-cell lymphoma (n=325, incidence 6.86 vs 3.79 per 100,000 person-years; adjusted HR 2.01, 1.48-2.75) and other or unknown subtypes (n=591, incidence 10.5 vs 7.07 per 100,000 person-years; adjusted HR 1.65, 1.29-2.11), compared with HBsAg negativity.
  • HBsAg positivity was not associated with follicular or T-cell NHL, Hodgkin's lymphoma, multiple myeloma, or various leukaemias.
  • INTERPRETATION: During extended follow-up, HBsAg-positive individuals had an increased risk of NHL, suggesting that chronic HBV infection promotes lymphomagenesis.
  • [MeSH-major] Hepatitis B, Chronic / complications. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Republic of Korea. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Gastroenterol Hepatol. 2000 Dec;15(12):1356-61 [11197043.001]
  • [Cites] Intern Med J. 2010 Sep;40(9):633-41 [19811561.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Feb;16(2):215-9 [11207904.001]
  • [Cites] Jpn J Cancer Res. 2002 May;93(5):471-7 [12036441.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):457-62 [12172038.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):341-8 [15141135.001]
  • [Cites] Clin Liver Dis. 2004 May;8(2):403-18 [15481347.001]
  • [Cites] Gut. 1996;38 Suppl 2:S63-6 [8786058.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1851-6 [15601641.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Mar 15;21(6):653-62 [15771751.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Haematologica. 2006 Apr;91(4):554-7 [16585021.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):197-203 [16684579.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2078-85 [17119031.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] Hepatology. 2007 Apr;45(4):1056-75 [17393513.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):132-7 [17635237.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1378-83 [18042694.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):x-xii [18271007.001]
  • [Cites] Ann Intern Med. 2008 Apr 1;148(7):519-28 [18378948.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Ann Hematol. 2008 Jun;87(6):475-80 [18327583.001]
  • [Cites] J Med Virol. 2008 Jun;80(6):960-6 [18428141.001]
  • [Cites] Autoimmun Rev. 2008 Oct;8(1):13-7 [18706529.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3069-75 [18957521.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):605-11 [19075267.001]
  • [Cites] Lancet. 2009 Feb 14;373(9663):582-92 [19217993.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Oct;7(10):1130-7 [19577007.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55 [19759364.001]
  • [Cites] Int J Hematol. 2009 Dec;90(5):601-4 [19802732.001]
  • [CommentIn] Lancet Oncol. 2010 Sep;11(9):806 [20688565.001]
  • (PMID = 20688564.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010176-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS218822; NLM/ PMC2933963
  •  go-up   go-down


82. Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Severson RK, Lynch CF, Wang SS, Maurer MJ, Hartge P, Cerhan JR: Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer; 2010 Jun 15;116(12):2993-3000
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study.
  • BACKGROUND: Smoking, alcohol use, and obesity appear to increase the risk of developing non-Hodgkin lymphoma (NHL), but to the authors' knowledge, few studies to date have assessed their impact on NHL prognosis.
  • These results held for lymphoma-specific survival and were broadly similar for diffuse large B-cell lymphoma and follicular lymphoma.
  • CONCLUSIONS: NHL patients who smoked, consumed alcohol, or were obese before diagnosis were found to have a poorer overall and lymphoma-specific survival.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3161-9 [18990758.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2694-702 [18633131.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):1930-2 [19289610.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1185-91 [11149729.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3 [12142963.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):436-41 [15314511.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Am J Epidemiol. 1994 Jun 15;139(12):1190-6 [8209877.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1476-82 [10424754.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):995-1007 [16418498.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1283-9 [16728483.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):564-9 [17454600.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5439-46 [17327408.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):599-612 [17646865.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1127-30 [17650444.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1624-9 [18059029.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4060-2 [18757320.001]
  • [Cites] Leukemia. 2009 Mar;23(3):596-602 [18830263.001]
  • (PMID = 20564404.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274-080003; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / CA / CA097274-080003; United States / NCI NIH HHS / PC / N01-PC-67,009; United States / NCI NIH HHS / PC / N01-PC-67,008; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67,010; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R01 CA096704; United States / NCI NIH HHS / CA / R01 CA96704; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / PC / N02-PC-71,105; United States / NCI NIH HHS / CA / R01 CA096704-05; United States / NCI NIH HHS / CA / CA096704-05; United States / NCI NIH HHS / CA / P50 CA97274; United States / NCI NIH HHS / PC / N01-PC-65,064
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS182481; NLM/ PMC2889918
  •  go-up   go-down


83. Reiter A, Klapper W: Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol; 2008 Jul;142(3):329-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
  • Diffuse large B-cell lymphomas (DLBCL) are neoplasms of transformed mature B cells, accounting for approximately 10% of non-Hodgkin lymphomas (NHL) of childhood.
  • Clinical features of children with DLBCL differ from those with other NHL entities, e.g. by a lower frequency of bone-marrow and central nervous system involvement.
  • Treatment strategies originally designed for Burkitt lymphoma appear to be efficacious for children with DLBCL.
  • However, children with primary mediastinal large B-cell lymphoma may need a more specific treatment approach, given their inferior outcome in recent studies.
  • The availability of new methodological tools, such as gene expression profiling, will greatly enhance our insights into the biology of childhood DLBCL and its similarities and disparities compared to adult DLBCL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Clinical Trials as Topic. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Humans. Immunophenotyping. Lymph Nodes / immunology. Prednisone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537979.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 102
  •  go-up   go-down


84. Lombardi VR, Martínez E, Chacón R, Etcheverría I, Cacabelos R: Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma. J Biomed Biotechnol; 2009;2009:187015
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.
  • The present study evaluated the screening efficacy of flow cytometric lymphocyte subset typing in peripheral blood mononuclear cells from healthy individuals (HI) and from patients with non-Hodgkin lymphoma (NHL) treated with different concentrations of FR-91, a standardized lysate of microbial cells belonging to the Bacillus genus, and in vitro cytokine production.
  • Increased expression of subset markers (CD3, CD4, CD8) in NHL and CD3 in HI suggests an immunomodulating effect of FR-91.
  • In a similar manner an increase of IL-2, IL-6, IL-12, IFN-gamma and TNF-alpha was also observed in the NHL group.
  • In conclusion FR-91 seems to affect lymphocyte subpopulations, in vitro cytokine production, as well as mitogen-induced lymphocyte activation in a dose-dependent manner in both healthy individuals and NHL patients.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Bacillus / immunology. Leukocytes, Mononuclear / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Analysis of Variance. Antigens, CD / blood. Cell Extracts / immunology. Cell Extracts / pharmacology. Concanavalin A / pharmacology. Flow Cytometry. Humans. Interleukins / biosynthesis. Interleukins / immunology. Lymphocyte Activation. Lymphocyte Subsets / immunology. Lymphocytes / drug effects. Lymphocytes / immunology. Middle Aged. T-Lymphocytes / drug effects. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 2004 Jun;20(6):636-41 [15242540.001]
  • [Cites] Cell Immunol. 2002 Sep;219(1):22-7 [12473264.001]
  • [Cites] Chest. 2004 Nov;126(5):1645-55 [15539739.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):245-54 [15888247.001]
  • [Cites] Immunobiology. 2008;213(2):97-108 [18241694.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):108-13 [18298334.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2008;30(1):53-70 [18306104.001]
  • [Cites] Respir Med. 2008 Mar;102(3):321-7 [18164190.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):65-8 [18477047.001]
  • [Cites] Curr Mol Med. 2008 Jun;8(4):282-98 [18537636.001]
  • [Cites] Curr Pharm Des. 2008;14(14):1351-67 [18537658.001]
  • [Cites] Anaerobe. 2008 Jun;14(3):166-71 [18396068.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2008 Jun;8(3):243-8 [18560300.001]
  • [Cites] J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S91-6 [18542035.001]
  • [Cites] J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S75-9 [18542038.001]
  • [Cites] Expert Rev Anti Infect Ther. 2008 Aug;6(4):497-508 [18662116.001]
  • [Cites] Scand J Immunol. 2006 Jan;63(1):26-34 [16398698.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40(3):232-4 [16633128.001]
  • [Cites] Nutr Hosp. 2006 May;21 Suppl 2:72-84, 73-86 [16771075.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 1;24(5):701-14 [16918875.001]
  • [Cites] Respir Med. 2006 Oct;100(10):1671-81 [16934969.001]
  • [Cites] Med J Aust. 2006 Aug 21;185(4 Suppl):S4-24 [17022438.001]
  • [Cites] Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):551-9 [17026840.001]
  • [Cites] Eur J Pharmacol. 2007 Jan 26;555(2-3):211-7 [17109845.001]
  • [Cites] J Appl Microbiol. 2007 Feb;102(2):337-43 [17241338.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53 [17255288.001]
  • [Cites] Pak J Pharm Sci. 2007 Jan;20(1):76-82 [17337434.001]
  • [Cites] Cytotherapy. 2007;9(2):123-32 [17453964.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2007 May;145(4):553-81 [17392033.001]
  • [Cites] Plant Foods Hum Nutr. 2007 Jun;62(2):79-84 [17577669.001]
  • [Cites] Clin Lab Med. 2007 Sep;27(3):513-32, vi [17658405.001]
  • [Cites] Br J Nutr. 2007 Oct;98 Suppl 1:S96-100 [17922969.001]
  • [Cites] J Microbiol Biotechnol. 2008 Jul;18(7):1278-85 [18667857.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2008;111:1-66 [18461293.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 Sep;11(5):640-4 [18685462.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Scand J Immunol. 2008 Sep;68(3):287-96 [18782257.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):782-98 [18813321.001]
  • [Cites] Nat Rev Microbiol. 2008 Nov;6(11 Suppl):S7-15 [18923413.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6207-15 [18931688.001]
  • [Cites] Immunobiology. 2008;213(8):677-92 [18950596.001]
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2007;2(3):335-45 [18229572.001]
  • [Cites] J Neuroimmunol. 2002 Jun;127(1-2):22-9 [12044971.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Dec;156(6):1719-24 [9412546.001]
  • (PMID = 19606255.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD; 0 / Cell Extracts; 0 / Interleukins; 11028-71-0 / Concanavalin A
  • [Other-IDs] NLM/ PMC2709720
  •  go-up   go-down


85. Jevtovic-Stoimenov T, Kocic G, Pavlovic D, Macukanovic-Golubovic L, Marjanovic G, Djordjevic V, Tosić N, Pavlović S: Polymorphisms of tumor-necrosis factor-alpha - 308 and lymphotoxin-alpha + 250: possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells. Leuk Lymphoma; 2008 Nov;49(11):2163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of tumor-necrosis factor-alpha - 308 and lymphotoxin-alpha + 250: possible modulation of susceptibility to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononuclear cells.
  • TNF-alpha and LT-alpha are highly produced in chronic lymphotic leukemia (CLL) and non-Hodgkin lymphoma (NHL) patients.
  • Study was performed on mononuclear cells of CLL and NHL patients.
  • The study provided evidence of the influence of TNFG/A genotype and A alleles in the susceptibility to NHL, since the association of LT-alphaG/G genotype with CLL was observed.
  • High-producing TNF-alpha - 308/LT-alpha + 250 heterozygous haplotype is associated with high NHL incidence.
  • The investigated SNP influence the activity of alkaline DNase in CLL and NHL patients.
  • [MeSH-major] Apoptosis / genetics. Genetic Predisposition to Disease. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphotoxin-alpha / genetics. Polymorphism, Genetic. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA Fragmentation. Deoxyribonucleases / metabolism. Female. Humans. Leukocytes, Mononuclear / pathology. Male. Middle Aged. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021060.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha; EC 3.1.- / Deoxyribonucleases
  •  go-up   go-down


86. Guzicka-Kazimierczak R: [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors]. Ann Acad Med Stetin; 2006;52(3):77-84; discussion 84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric non-Hodgkin's lymphoma: clinical findings and prognostic factors].
  • PURPOSE: This work was undertaken to determine the clinical course and prognostic factors in patients with primary gastric non-Hodgkin's lymphoma (NHL).
  • The diagnosis of primary gastric NHL was made on the basis of histopathologic examination of samples collected during gastroscopy in 50 or gastrectomy in 14 patients.
  • A retrospective analysis was performed of the relationship between the outcome of treatment and age, gender, histological type of the lymphoma, clinical staging according to the original Ann Arbor classification and as modified by Stein and coworkers, functional status according to the ECOG scale, International Prognostic Index, type of lymphoma according to the classification of Kramer, and type of primary therapy.
  • The clinical picture of primary gastric non-Hodgkin's lymphoma is unrevealing.
  • 2. Age, gender, functional status, histological type of the lymphoma, and clinical stage do not correlate with treatment outcome and survival.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Agents / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385352.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Ansell SM, Novak AJ, Ziesmer S, Price-Troska T, LaPlant B, Dillon SR, Witzig TE: Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am J Hematol; 2009 Feb;84(2):71-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.
  • Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene.
  • In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Follicular lymphoma 1.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2002 Jul;2(7):465-75 [12094221.001]
  • [Cites] Leuk Res. 2009 Jan;33(1):162-5 [18556064.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15 [12652459.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):995-9 [10801128.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):785-8 [10898980.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Immunity. 2001 Aug;15(2):289-302 [11520463.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17789-94 [15591344.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1103-8 [15657404.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):983-7 [16432079.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):723-32 [16508933.001]
  • [Cites] Immunology. 2006 Jul;118(3):281-92 [16827889.001]
  • [Cites] Arthritis Res Ther. 2006;8(6):R167 [17092341.001]
  • [Cites] Ann Rheum Dis. 2007 May;66(5):700-3 [17040963.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1464-77 [17469105.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1284-5 [17768131.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • (PMID = 19051265.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121569; United States / NCI NIH HHS / CA / R21 CA121569-02; United States / NCI NIH HHS / CA / CA121569-02; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / R21 CA121569
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / B-Cell Activating Factor; 0 / Neoplasm Proteins; 0 / TNFSF13B protein, human; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS123246; NLM/ PMC2774736
  •  go-up   go-down


88. Yao B, Li YX, Fang H, Jin J, Liu XF, Yu ZH: [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases]. Ai Zheng; 2006 Apr;25(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of primary non-Hodgkin's lymphoma (NHL) of the nasal cavity was poor, and the distant metastasis and local relapse rates are high.
  • METHODS: Clinical data of 129 patients with pathologically confirmed nasal NHL, treated from Jan.
  • Of the 129 patients, 116 were diagnosed as nasal NK/T-cell lymphoma.
  • CONCLUSIONS: CR rate after treatment is an important prognostic factor of nasal NHL.
  • Distant metastasis is the main failure pattern of nasal NHL.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613682.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


89. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR: Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2009 Feb;15(2):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
  • The hematopoietic cell transplantation comorbidity index (HCT-CI), a weighted index of 17 pretransplantation comorbidities, has been validated in nonmyeloablative and myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) studies, but it has not been specifically tested in patients with non-Hodgkin lymphoma (NHL) receiving reduced-intensity conditioning (RIC).
  • We performed a retrospective analysis to assess the impact of the HCT-CI on outcomes of NHL patients treated with HSCT relative to treatment-related mortality (TRM), disease-related mortality (DRM), with a specific emphasis on overall survival (OS).
  • The analysis included 63 NHL patients with a median HCT-CI score of 2 (range, 0 to 11).
  • Although HCT-CI may be useful for predicting TRM, our data further underscore the importance of response to chemotherapy before transplantation as a predictor of overall transplantation outcome in NHL patients being considered for RIC allogeneic HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / mortality. Lymphoma, Non-Hodgkin / therapy. Severity of Illness Index. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Cause of Death. Comorbidity. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4022-31 [12351600.001]
  • [Cites] Int J Hematol. 2002 Aug;76 Suppl 1:184-9 [12430851.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3713-5 [12963698.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2419-23 [15197204.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Sep;10(9):579-90 [15319770.001]
  • [Cites] JAMA. 1993 Jul 7;270(1):57-60 [8510297.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] Am J Med. 1996 Mar;100(3):299-307 [8629675.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3797-803 [15280203.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3439-46 [15824415.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Aug;11(8):593-9 [16041309.001]
  • [Cites] Bone Marrow Transplant. 2005 Sep;36(6):475-9 [15995717.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60 [17085308.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3340-9 [11454881.001]
  • (PMID = 19167682.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA BC010698-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS185550; NLM/ PMC2842937
  •  go-up   go-down


90. Ling JY, Sun XF, Zhang X, Zhen ZJ, Xia Y, Luo WB, Lin H, Zheng L: [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL]. Ai Zheng; 2008 Oct;27(10):1065-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic changes of serum proteomic spectra in patients with non-Hodgkin's lymphoma (NHL) before and after chemotherapy and screening of candidate biomarkers for NHL].
  • BACKGROUND & OBJECTIVE: Although the complete response rate of non-Hodgkin's lymphoma (NHL) is 70%-80% using modern comprehensive treatments, its relapse rate is about 40%-50%.
  • This study was to detect dynamic changes of serum proteomic spectra in NHL patients before and after chemotherapy, thus to screen candidate markers for NHL.
  • METHODS: The proteomic spectra from serum of 44 NHL patients before chemotherapy, 44 NHL patients who achieved complete remission (CR) after chemotherapy, and 51 healthy individuals were analyzed by surface-enhanced laser desorption/ ionization time of flight mass spectrometry (SELDI-TOF-MS) and Ciphergen ProteinChip 3.1 software.
  • RESULTS: Compared with the normal group, one protein peak (M11710) was up-regulated in untreated NHL group, while was close to the normal level in CR group (P < 0.05); nine other protein peaks (M3322, M4355, M6445, M6646, M8581, M8708, M8918, M13959, M15149) were down-regulated in untreated NHL group, while were close to normal levels in CR group(P < 0.05).
  • Five candidate biomarkers for NHL were screened using the decision tree model.
  • CONCLUSIONS: Expressions of serum proteomic spectra are different before and after chemotherapy in NHL patients.
  • Protein signatures of NHL may be screened using SELDI mass spectrometry combined with ProteinChip software.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Profiling. Lymphoma, Non-Hodgkin / blood. Proteome / analysis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Decision Trees. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / blood. Protein Array Analysis. Remission Induction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851786.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


91. Beck Z, Illés A, Keresztes K, Bessenyei B, Szöllosi Z, Kis A, Oláh E: [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?]. Orv Hetil; 2006 Aug 20;147(33):1539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
  • [Transliterated title] Az Epstein-Barr-vírus ZEBRA fehérjéjének expressziója magyarországi Hodgkin-lymphomás betegekben: latens vagy litikus ciklus?
  • The virus is associated with an increasing number of lymphoid malignancies, such as Hodgkin and non-Hodgkin lymphomas.
  • Although the presence of ZEBRA protein induces lytic cycle, some lymphoma cases show this protein expression.
  • AIM: In our present study we investigated the frequency of expression of ZEBRA protein in Hungarian patients with Hodgkin lymphoma associated with Epstein-Barr virus infection.
  • The authors wanted to clarify whether this expression is specific to latency type II or occurs in some non-Hodgkin lymphoma cases with latency type III as well.
  • METHOD: 109 HL and 59 NHL were studied for the presence of the virus in the tumor and for expression of the latency proteins and ZEBRA by immunohistochemistry.
  • We detected the weak expression of ZEBRA protein in 13 of the 25 LMP1 positive Hodgkin lymphoma cases and in 6 of the 18 LMP1 positive non-Hodgkin lymphoma samples.
  • [MeSH-major] DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / virology. Trans-Activators / analysis. Viral Proteins / analysis
  • [MeSH-minor] Adult. Aged. Epstein-Barr Virus Nuclear Antigens / analysis. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Hungary. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037676.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA-Binding Proteins; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  •  go-up   go-down


92. Elberling C, Don M, Cebulla M, Stürzebecher E: Auditory steady-state responses to chirp stimuli based on cochlear traveling wave delay. J Acoust Soc Am; 2007 Nov;122(5):2772-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The auditory steady-state responses to these chirps and to a click stimulus are compared at two levels of stimulation (30 and 50 dB nHL) and a rate of 90s.
  • [MeSH-minor] Adolescent. Adult. Humans. Models, Biological. Reaction Time. Reference Values

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189568.001).
  • [ISSN] 1520-8524
  • [Journal-full-title] The Journal of the Acoustical Society of America
  • [ISO-abbreviation] J. Acoust. Soc. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ: [Correlation of hepatitis B virus infection to non-Hodgkin's lymphoma]. Ai Zheng; 2007 Mar;26(3):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of hepatitis B virus infection to non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: Previous studies showed that the infection rate of hepatitis B virus (HBV) is higher in non-Hodgkin's lymphoma (NHL) patients than in non-primary liver cancer solid tumor patients and general population in the same region, but the correlation of HBV infection to NHL is inconclusive.
  • This study was to compare HBV infection rate of NHL patients with that of non-primary liver cancer solid tumor patients, and explore the correlation of HBV infection to NHL.
  • METHODS: The infection of hepatitis B virus surface antigen (HBsAg) in 109 NHL patients and 128 colorectal carcinoma patients was detected.
  • RESULTS: The positive rate of HBsAg was significantly higher in NHL patients than in colorectal carcinoma patients and general population (40.4% vs. 14.1% and 17.3%, P<0.01).
  • Regarding colorectal carcinoma patients as a reference group, odds ratio (OR) of NHL in HbsAg-positive population was 2.87, and the 95% confidence interval (95% CI) was 1.830-4.502.
  • CONCLUSION: The positive rate of HBsAg is higher in NHL patients than in colorectal carcinoma patients and general population.
  • [MeSH-major] Colorectal Neoplasms / virology. Hepatitis B Surface Antigens / blood. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Confidence Intervals. Female. Hepatitis B / immunology. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / virology. Male. Odds Ratio. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355794.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


94. Navarro JT, Vall-Llovera F, Mate JL, Morgades M, Feliu E, Ribera JM: Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica; 2008 Jan;93(1):149-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART.
  • We evaluated the frequency of primary central nervous system lymphoma and leptomeningeal involvement in systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients.
  • Those receiving highly active antiretroviral therapy (HAART) showed a decrease in leptomeningeal involvement in systemic NHL (0/30 vs. 12/87; p=0.023).
  • Therefore HAART could prevent CNS involvement in systemic NHL.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / prevention & control. Meninges / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Prognosis. Retrospective Studies. Time Factors


95. Batlle M, Ribera JM, Oriol A, Pastor C, Mate JL, Fernández-Avilés F, Flores A, Millá F, Feliu E: Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leuk Lymphoma; 2005 Oct;46(10):1471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
  • CA 125 and CA 15.3 serum levels were measured at diagnosis, after treatment and at the time of recurrence in 200 consecutive patients (114 males, median age 56 years) with non-Hodgkin's lymphoma (NHL) to explore its usefulness in the evaluation of response to treatment and survival in patients with NHL compared to lactate dehydrogense (LDH) and beta2-microglobulin (beta2-M).
  • When elevated at diagnosis, CA 125 and CA 15.3 should be monitored during follow-up of patients with NHL.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis. Mucin-1 / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194893.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Mucin-1
  •  go-up   go-down


96. Wöhrer S, Raderer M, Kaufmann H, Hejna M, Chott A, Zielinski CC, Drach J: Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. Onkologie; 2005 Feb;28(2):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
  • Since indolent non-Hodgkin's lymphomas (NHL) represent about 35% of all malignant lymphomas and mainly affect elderly patients, availability of a conventional chemotherapy regimen with high efficacy and low toxicity is of clinical importance.
  • PATIENTS AND METHODS: We retrospectively analysed 13 patients with advanced indolent NHL who were treated with 6-9 cycles of MCP: mitoxantrone 8 mg/m2 (days 1 and 2), chlorambucil 3 x 3 mg/m2 (days 1-5) and prednisone 25 mg (days 1-5) every 4 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Retrospective Studies. Severity of Illness Index. Treatment Outcome

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662110.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCP protocol
  •  go-up   go-down


97. Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF: Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant; 2005 Aug;36(3):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median recovery was 93% (range 48-107%), with 90% recovery for NHL (range 48-100%, n=34), 83% for multiple myeloma (range 56-106%, n=11), 92.3% for acute leukemia (range 71-100% n=7) and 94.5% for nonhematological malignancies (range 50-107% n=18).
  • The recovery of viable CD34+ cells for adult (n=51) and pediatric (n=28) stem cell collections was 91 and 94%, respectively.
  • [MeSH-minor] Bone Marrow. Bone Marrow Cells / cytology. Cell Separation / methods. Cryopreservation. Graft Survival. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Humans. Kinetics. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937512.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


98. Zhou M, Cen L, Xue YQ: [Analysis of the non-Hodgkin lymphoma's clinic and blood marrow cytogenetics]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct;23(5):568-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the non-Hodgkin lymphoma's clinic and blood marrow cytogenetics].
  • OBJECTIVE: To analyze the relationship among cytogenetics, hematopathology, morphology, clinic tumor index and prognosis of the non-Hodgkin lymphoma(NHL) patients.
  • METHODS: Cytogenetics analysis of bone marrow cells was performed by direct method and 24 h culture method in 20 cases of NHL.
  • RESULTS: Out of the twenty NHL patients, eight had bone marrow infiltration, and nine were found with abnormal karyotype: three were chromosome number abnormalities, one was t(14,18)(q32;q21), one was 14q+, two were t(8;14)(q24;q32), two were t(8;14)(q24;q32) with additional changes of chromosome.
  • CONCLUSION: t(8;14) (q24;q32) is the most classic translocation in NHL, The patients with this karyotype have worse prognosis.
  • [MeSH-major] Bone Marrow Cells / metabolism. Cytogenetics / methods. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosome Aberrations. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Translocation, Genetic. Tumor Suppressor Protein p53 / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029212.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


99. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant; 2008 Jan;14(1):36-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
  • Although results of autologous stem cell transplantation (SCT) for recurrent follicular non-Hodgkin lymphoma (NHL) have been previously reported, the long-term results and evaluation of prognostic factors in a large patient population receiving this therapy are difficult to find in the literature.
  • To address these issues, we evaluated 248 patients with recurrent follicular NHL treated with high-dose chemotherapy and autologous SCT between 7/87 and 6/03.
  • According to the World Health Organization (WHO) classification system, 64 patients (26%) had follicular NHL grade 1 (FL 1), 98 (40%) had FL 2, and 86 (35%) had FL 3.
  • At the time of transplantation, 88 of the patients (35%) had a Follicular Lymphoma International Prognostic Index (FLIPI) score of low risk, 87 (35%) had an intermediate-risk FLIPI score, 37 (15%) had a high-risk FLIPI score, and 36 (15%) had at least 1 missing value, preventing calculation of the FLIPI score.
  • In addition, the use of a transplantation regimen including a monoclonal antibody decreased the relative risk of progressive lymphoma.
  • These data suggest that transplantation earlier in the course of the disease for patients with follicular lymphoma with use of a monoclonal antibody-based regimen may lead to improved outcomes.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / therapy. Severity of Illness Index
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Risk Assessment. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Autologous / adverse effects. Transplantation, Autologous / methods. Treatment Outcome. Whole-Body Irradiation / adverse effects


100. Gang AO, Arpi M, Gang UJ, Vangsted AJ: Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma. Hematology; 2010 Aug;15(4):222-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma.
  • The population included non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) patients.
  • CONCLUSION: The frequency of isolated pathogens, positive blood cultures, and the diversity of pathogens were higher in MM patients as compared to NHL patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Opportunistic Infections / epidemiology. Opportunistic Infections / microbiology. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Ambulatory Care. Anti-Infective Agents / pharmacology. Anti-Infective Agents / therapeutic use. Antibiotic Prophylaxis. Female. Fungi / drug effects. Fungi / isolation & purification. Giardia lamblia / drug effects. Giardia lamblia / isolation & purification. Gram-Negative Bacteria / drug effects. Gram-Negative Bacteria / isolation & purification. Gram-Positive Bacteria / drug effects. Gram-Positive Bacteria / isolation & purification. Humans. Male. Middle Aged. Retrospective Studies. Young Adult






Advertisement